**Table F-2. Comorbid conditions, quality of life, impairment, and ability to return to work**

| Author, Year | Intervention Groups | Comorbid Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Acarturk et al., 2016[44](#_ENREF_44) | G1: EMDR-R-TEP  G2: WL | BDI-II  Mean (SE at pre-tx; SD at post-tx and followup)  G1 Pre-tx:29.85 (9.27)  G1 Post-tx: 10.45 (1.73)  G1 1 month followup: 12.85 (1.98)  G2 Pre-tx: 28.53 (7.99)  G2 Post-tx: 26.35 (1.68)  G2 1 month followup: 26.13 (1.87)  G1 vs G2 pre to posttreatment p<0.001  G1 vs G2 pretreatment to followup p<0.001  Treatment X Time, F = 0.76, p = 0.368 from posttreatment to followup  Mean estimated difference, post-tx: -15.90 (95% CI, -20.20 to -11.09), p <0.001  Mean estimated difference, 1 month followup: -13.28 (95% CI, -18.73 to -7.82),  p <0.001  HSCL  Mean (SE at pre-tx; SD at post-tx and followup)  G1 Pre-tx:2.65 (0.50)  G1 Post-tx: 1.54 (0.09)  G1 1 month followup: 1.73 (0.10)  G2 Pre-tx: 2.46 (0.44)  G2 Post-tx: 2.34 (0.09)  G2 1 month followup: 2.34 (0.09) | NR | NR | NR |

| Author, Year | Intervention Groups | | Comorbid Condition | | QOL | | Disability/Functional Impairment | | Return to Work/Active Duty OR Ability to Work | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Acarturk et al., 2016[44](#_ENREF_44)  (continued) | |  | | G1 vs G2 pre to posttreatment p<0.001  G1 vs G2 pretreatment to followup p<0.001  Treatment X Time, F = 1.79, p = 0.186 from posttreatment to followup  Mean estimated difference, post-tx: -0.89 (95% CI, -1.15 to -0.64), p <0.001  Mean estimated difference, 1 month followup: -0.78 (95% CI, -0.96 to -0.43),  p <0.001 | |  | |  | |  |
| Acosta et al., 2017[149](#_ENREF_149) | | G1: Web CBT plus TAU (Thinking Forward and usual VA primary care services)  G2: TAU, usual VA primary care services | | Percent of drinking days  Treatment by time effect, NS during treatment period, Estimate: -0.93 (1.12)  Treatment by time effect, NS contrasting between in and post-treatment, Estimate: 1.67 (1.84)  Percent of heavy drinking days  Treatment by time effect, during treatment period, Estimate: -1.80 (0.79), p<0.05  Treatment by time effect, NS contrasting between in and post-treatment, Estimate: 1.89 (1.33)  Percent of drug use days  Treatment by time effect, NS during treatment period, Estimate: -0.27 (0.25)  Treatment by time effect, NS contrasting between in and post-treatment, Estimate: -0.06 (0.49) | | QOL – Physical domain  Treatment by time effect, NS during treatment period, Estimate: 0.75 (0.52)  Treatment by time effect, NS contrasting between in and post-treatment, Estimate: -0.51 (0.91)  QOL – psychological domain  Treatment by time effect, NS during treatment period, Estimate: 0.77 (0.58)  Treatment by time effect, NS contrasting between in and post-treatment, Estimate: -0.88 (0.94)  QOL – social domain  Treatment by time effect, NS during treatment period, Estimate: 1.27 (1.02) | | NR | | NR |

| Author, Year | Intervention Groups | | Comorbid Condition | | QOL | | Disability/Functional Impairment | | Return to Work/Active Duty OR Ability to Work | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Acosta et al., 2017[149](#_ENREF_149)  (continued) | |  | |  | | Treatment by time effect, NS contrasting between in and post-treatment, Estimate: -2.00 (1.72)  QOL – environment domain  Treatment by time effect, NS during treatment period, Estimate: 0.13 (0.61)  Treatment by time effect, NS contrasting between in and post-treatment, Estimate: 0.15 (1.02) | |  | |  |
| Akuchekian et al., 2004[77](#_ENREF_77) | | G1: Topiramate  25 to 500 mg/day (sensitive patients started at 12.5mg/day)  G2: Placebo | | NR | | NR | | NR | | NR |
| Asukai et al., 2010[10](#_ENREF_10) | | G1: CBT, exposure-based therapy  G2: UC | | CES-D  Adjusted Means (SE)  G1 Pre-tx:39.58 (3.53)  G1 Post-tx: 20.30 (3.97)  G2 Pre-tx:39.50 (3.52)  G2 Pre-tx: 34.81 (3.65)  At post: G1 vs. G2=  p<0.05(based on t-test) | | GHQ-28 Adjusted Means (SE)  G1 Pre-tx:21.58 (1.89)  G1 Post-tx: 10.04 (2.15)  G2 Pre-tx:20.50 (1.89) G2 Post-tx: 17.65 (1.97)  At post: G1 vs. G2=  p<0.05(based on t-test) | | NR | | NR |

| Author, Year | Intervention Groups | Comorbid Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Bartzokis et al., 2005[86](#_ENREF_86) | G1: Risperidone  1 to 3 mg/day  G2: Placebo | HAM-A  Unadjusted Change from baseline (SD)  G1: -7.4 (5.7)  G2:-2.0 (7.0)  G1 vs. G2, p<0.001  HAM-D  Unadjusted Change from baseline (SD)  G1: -3.7 (8.0)  G2: -1.4 (8.7)  G1 vs. G2, p>0.05 | NR | NR | NR |
| Basoglu et al., 2007[11](#_ENREF_11) | G1: CBT, exposure-based therapy  G2: WL | BDI Mean (SD) G1 Pre-tx:23.4 (5.9) G1 4 weeks:13.1 (6.2) G1 8 weeks: 13.3 (9.2)  G2 Pre-tx:21.9 (3.5) G2 4 weeks: 20.5 (7.4) G2 8 weeks:18.4 (11.0)  G1 vs. G2 at Week 4, p<0.01  G1 vs. G2 at Week 8, p<0.007 | NR | Work and Social Adjustment Mean (SD) G1 Pre-tx: 4.1 (0.8) G1 4 weeks: 2.2 (1.4) G1 8 weeks: 1.7 (1.9)  G2 Pre-tx: 4.1 (0.9) G2 4 weeks:3.3 (1.4) G2 8 weeks:2.7 (1.6)  G1 vs. G2 at Week 4, p<0.01  G1 vs. G2 at Week 8, p<0.007 | NR |
| Batki et al., 2014[165](#_ENREF_165) | G1: Topiramate  25 to 300mg  G2: Placebo | Alcohol consumption  % Drinking Days  Between-group analysis  Weeks 1 to 12 Avg.  G1: 19.5 (34.2)  G2: 39.7 (36.5)  P p = 0.036, IRR = 0.38, 95% CI 0.15 to-0.94, % diff. = 51  Main Effects of treatment, p = 0.063, IRR = 0.430; 95% CI = 0.18 to-1.05 | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Batki et al., 2014[165](#_ENREF_165)  (continued) |  | %Heavy Drinking Days  Between-group analysis  Weeks 1 to 12 Avg.  G1: 11.1 (27.1)  G2: 16.8 (26.3)  P p = 0.342, IRR = 0.56, 95% CI 0.17 -to 1.87, % diff. = 34  Standard Drinks per week  Between-group analysis  Weeks 1 to 12 Avg.  G1: 8.7 (19.0)  G2: 19.3 (30.5)  P p = 0.099, IRR = 0.43, 95% CI 0.16 to-1.17, % diff. = 55  Drinks per Drinking Day  Between-group analysis  Weeks 1 to 12 Avg.  G1: 1.9 (3.3)  G2: 4.8 (6.5)  P p = 0.057, IRR = 0.45, 95% CI 0.20 to-1.02, % diff. = 60  OCDS (Alcohol cravings)  Between-group analysis  Weeks 1 to 12 Avg.  G1: 5.53 (6.55)  G2: 11.08 (8.12)  P p = 0.025, IRR = -7.02, 95% CI= -13.1 to 0.91, % diff. = 50  Main Effects of treatment, F (1,48) = 2.81, p = 0.100 |  |  |  |

| Author, Year | Intervention Groups | Comorbid Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Becker et al., 2007[183](#_ENREF_183) | G1: Bupropion  100 to 300 mg/day  G2: Placebo | BDI  Within-Group Mean Change (SD) (Baseline-Endpoint)  G1: 3.22 (4.77) G2: 3.61 (10.44)  Group effect, p<0.05 | NR | NR | NR |
| Blanchard et al., 2003[36](#_ENREF_36) | G1: CBT-mixed  G2: Supportive psychotherapy  G3: WL | BDI  Mean (SD)  G1 Pre-tx: 24.3 (10.8)  G1 Post-tx: 11.6 (12.3)  G1 FU: 12.6 (13.5)  G2 Pre-tx: 17.8 (13.0)  G2 Post-tx: 56.3 (12.2)  G2 FU: 17.8 (13.0)  G3 Pre-tx: 25.2 (11.9)  G3 Post-tx: 24.0 (12.1)  Group X Time, Post-Tx  G1 vs. G2 & G3 (Post-tx) (Group X Time), p<0.001  G2 vs G3 (Post-tx) (Group X Time), NS No changes at 3 mths | NR | GAF  Mean (SD)  G1 Pre-tx: 53.9 (11.4)  G1 Post-tx: 75.8 (12.2)  G1 FU: 74.7 (12.8)  G2 Pre-tx: 56.0 (9.7)  G2 Post-tx: 64.3 (13.4)  G2 FU: 66.3 (15.1)  G3 Pre-tx: 56.0 (13.1)  G3 Post-tx: 60.4 (9.6)  Group X Time, Post-Tx  G1 vs. G2, p=0.001  G1 vs G3, p=0.001  G2 vs & G3, NS  No changes at 3 months | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Blanchard et al., 2003[36](#_ENREF_36)  (continued) |  | State-Anxiety  Mean (SD)  G1 Pre-tx: 55.3 (14.1)  G1 Post-tx: 38.9 (14.0)  G1 FU: 42.6 (15.4)  G2 Pre-tx: 56.3 (12.2)  G2 Post-tx: 50.7 (12.6)  G2 FU: 49.1 (14.5)  G3 Pre-tx: 58.5 (10.9)  G3 Post-tx: 58.8 (12.3)  Group X Time, Post-tx  G1 vs. G2 & G3, p<0.001  G2 vs. G3, significantly greater change for G2  Changes at 3 mths, NS  Trait-Anxiety  Mean (SD)  G1 Pre-tx: 55.7 (14.0)  G1 Post-tx: 41.0 (16.5)  G1 FU: 40.6 (15.3)  G2 Pre-tx: 56.7 (10.4)  G2 Post-tx: 52.4 (12.3)  G2 FU: 52.3 (12.6)  G3 Pre-tx: 58.9 (10.1)  G3 Post-tx: 57.7 (9.9)  Group X Time, Post-Tx  G1 vs. G2 & G3, p<0.001  G2 vs. G3, NS  Changes at 3 mths |  |  |  |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Blanchard et al., 2003[36](#_ENREF_36)  (continued) |  | Global Severity Index  Mean (SD)  G1 Pre-tx: 70.1 (9.3)  G1 Post-tx: 57.3 (12.6)  G1 FU: 58.4 (14.3)  G2 Pre-tx: 73.2 (6.4)  G2 Post-tx: 67.6 (9.0)  G2 FU: 65.3 (13.1)  Group X Time, Post-tx  G1 vs. G2 & G3, p<0.001  G2 vs. G3, significantly greater change for G2 |  |  |  |
| Boden et al., 2012[58](#_ENREF_58) | G1: Seeking Safety and TAU  G2: TAU | ASI  Drug Use  Mean (SD)  G1 Pre-tx: 0.09 (0.08)  G1 Post-tx: 0.06 (0.06)  G1 6 mth FU: 0.05 (0.06)  G2 Pre-tx: 0.11 (0.08)  G2 Post-tx: 0.10 (0.09)  G2 6 mth FU: 0.09 (0.09)  Between Group Differences at Post-tx, p<0.05  Between Group Differences at 6 month FU, p<0.05  G1 Within-Group Differences  Pre-tx vs. Post-tx, p<0.05  G1 Within-Group Differences  Pre-tx vs. 6mth FU, p<0.05 | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Boden et al., 2012[58](#_ENREF_58) (continued) |  | Alcohol Use  Mean (SD)  G1 Pre-tx: 0.29 (0.26)  G1 Post-tx: 0.17 (0.19)  G1 6 mth FU: 0.14 (0.17)  G2 Pre-tx: 0.23 (0.24)  G2 Post-tx: 0.15 (0.13)  G2 6 mth FU: 0.14 (0.15)  Between Group Differences, NS  G1 Within-Group Differences  Pre-tx vs. Post-tx, p<0.05  G1 Within-Group Differences  Pre-tx vs. 6 month FU, p<0.05  G2 Within-Group Differences  Pre-tx vs. Post-tx, p<0.05  G2 Within-Group Differences  Post-tx vs. 6 month FU, p<0.05 |  |  |  |

| Author, Year | Intervention Groups | Comorbid Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Bohus et al., 2013[23](#_ENREF_23) | G1: DBT-PTSD  G2: TAU-WL | BDI-II (ITT)  Mean (SD)  G1 Pre-tx: 38.00 (9.75)  G1 Post-tx: 26.81(11.45)  G1 18 week followup: 28.56 (10.62)  G1 24 week followup: 29.47 (12.61)  G2 Pre-tx: 39.53(9.13)  G2 Post-tx: 40.55 (10.59)  G2 18 week followup: 40.18 (11.10)  G2 24 week followup: 37.87 (12.62)  Hedges’ g between group: 0.70  Treatment X Time Interaction: -0.223 (0.089), p<0.0135  SCL-90-Revised (ITT)  Mean (SD)  G1 Pre-tx: 1.90 (0.66)  G1 Post-tx: 1.39(0.63)  G1 18 week followup: 1.38 (0.63)  G1 24 week followup: 1.41 (0.63)  G2 Pre-tx: 2.01(0.58)  G2 Post-tx: 1.94 (0.64)  G2 18 week followup: 1.81 (0.70)  G2 24 week followup: 1.73 (0.69)  Hedges’ g between group: 0.36  Treatment X Time Interaction: -0.002 (0.006), p=0.672 | NR | GAF (ITT)  Mean (SD)  G1 Pre-tx: 41.50 (4.50)  G1 Post-tx: 49.44(8.40)  G1 18 week followup: 51.33 (7.88)  G1 24 week followup: 51.08 (9.89)  G2 Pre-tx: 42.79(7.19)  G2 Post-tx: 43.79 (7.51)  G2 18 week followup: 42.92 (8.00)  G2 24 week followup: 42.92 (8.00)  Hedges’ g between group: 1.02  Treatment X Time Interaction: 0.503 (0.094), p<0.001 | NR |

| Author, Year | Intervention Groups | Comorbid Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Brady et al., 2000[66](#_ENREF_66) | G1: Sertraline  25 to 200 mg/day  G2: Placebo | HAM-D Mean Change (SEM) G1: -8.6 (1.3) G2: -5.0 (1.2) G1 vs. G2, p=0.04 | Q-LES-Q  Mean Change (SEM) G1: 11.7 (2.1) G2: 3.3 (16.7) G1 vs. G2, p=0.004 | CAPS social functioning subscale  Mean Change (SEM) G1:-1.2 (0.11) G2: -0.7 (0.11) G1 vs. G2, p=0.001  CAPS occupational functioning subscale  Mean change(Endpoint – Baseline) (SEM) G1:-0.7 (0.10) G2: -0.4 (0.10) G1 vs. G2, p=0.001 | NR |
| Brady et al., 2005[67](#_ENREF_67) | G1: Sertraline  150 mg/day  G2: Placebo | HAM-D ANOVA No significant between-group differences (p>0.05) | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Bryant et al., 2003[41](#_ENREF_41) | G1: CBT, exposure based therapy(PE)  G2: CBT-Mixed  Prolonged Imaginal Exposure plus CR  G3: Supportive Control | STAI-State  Mean (SD)  G1 Pre-tx: 56.80 (11.22)  G1 Post-tx: 43.10 (13.52)  G1 6 mth FU: 42.85 (14.90)  G2 Pre-tx: 54.60 (8.20)  G2 Post-tx: 41.45 (14.77)  G2 6 mth FU: 43.45 (11.85)  G3 Pre-tx: 56.28 (11.12)  G3 Post-tx: 51.50 (12.00)  G3 6 mth FU: 53.33 (9.70)  Post-tx, p<0.01 (main effects)  FU, p<0.05 (main effect)  BDI  Mean (SD)  G1 Pre-tx: 21.65 (11.18)  G1 Post-tx: 17.45 (12.82)  G1 6 mth FU: 16.15 (12.19)  G2 Pre-tx: 23.15 (10.05)  G2 Post-tx: 13.85 (14.31)  G2 6 mth FU: 14.95 (13.99)  G3 Pre-tx: 26.56 (11.15)  G3 Post-tx: 23.78 (12.10)  G3 6 mth FU: 25.33 (12.05)  Post-tx, p<0.01 (main effect)  FU, p<0.05 (main effect) | NR | Good End State Functioning at Followup (Being below specific cut-off scores for both PTSD and depression) G1: 15.0% G2: 40.0% G3: 0.0%  G1 vs. G3, p<0.01  G1 vs. G2, p<0.07 | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Bryant et al., 2008[42](#_ENREF_42) | G1: CBT, exposure based (Imaginal Exposure)  G2: CBT, exposure-based therapy (In vivo exposure)  G3: CBT, exposure-based therapy (Imaginal Exposure/In vivo Exposure)  G4: CBT-mixed  Imaginal Exposure/In vivo Exposure/ cognitive restructuring | STAI  Mean (SD)  G1 Pre-tx: 59.10 (15.08)  G1 Post-tx: 50.71 (16.36)  G1 6 mth FU: 56.19 (16.03)  G2 Pre-tx: 58.25 (15.62)  G2 Post-tx:50.36 (18.68)  G2 6 mth FU: 51.14 (17.88)  G3 Pre-tx: 59.32 (12.75)  G3 Post-tx:48.87 (16.74)  G3 6 mth FU: 54.84 (15.44)  G4 Pre-tx: 56.93 (12.75)  G4 Post-tx: 46.46 (17.21)  G4 6 mth FU: 46.89 (24.54)  Post-tx, NS (main effect)  6 month FU, NS (main effect)  BDI  Mean (SD)  G1 Pre-tx: 24.03 (10.81)  G1 Post-tx: 21.31 (13.23)  G1 6 mth FU: 20.58 (12.83)  G2 Pre-tx: 25.38 (12.82)  G2 Post-tx:19.36 (11.28)  G2 6 mth FU: 19.79 (12.43)  G3 Pre-tx: 24.23 (11.38)  G3 Post-tx: 22.16 (15.44)  G3 6 mth FU: 24.81 (14.90) | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Bryant et al., 2008[42](#_ENREF_42) (continued) |  | G4 Pre-tx: 21.79 (10.25)  G4 Post-tx:13.96 (12.05)  G4 6 mth FU: 13.54 (11.85)  Post-tx, NS (main effect)  6 month FU, p<0.05 (main effect) |  |  |  |
| Butterfield et al., 2001[82](#_ENREF_82) | G1: Olanzapine  5 to 20mg/day  G2: Placebo | NR | NR | SDS  Mean (SD) G1 Pre-tx: 19.8 (7.9) G2 Post-tx: 12.1 (7.8) Change: -7.7  G2 Pre-tx: 21.6 (7.2) G2 Post-tx: 13.6 (8.7) Change: -8.0  G1 vs. G2, no group X time differences found | NR |
| Carey et al., 2012[81](#_ENREF_81) | G1: Olanzapine  5 to 10mg  G2: Placebo | MADRS  Mean (SD)  G1 Pre-tx: 15.9 (4)  G1 Post-tx 8 week: 10.3 (6.8)  G2 Pre-tx: 15.3 (2.9)  G2 Post-tx 8 week: 15.3 (9.8)  Week 8 G1 vs. G2, p = 0.137, Effect size, r = 0.29 | NR | SDS  Mean (SD)  G1 Pre-tx: 18.3 (7.1)  G1 Post-tx 8 week: 10.6 (6.9)  G2 Pre-tx: 24.1 (4.2)  G2 Post-tx 8 week: 20.6 (7.4)  Week 8 G1 vs. G2, p = 0.004, Effect size, r = 0.57 | NR |

| Author, Year | Intervention Groups | Comorbid Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Carlson et al., 1998[46](#_ENREF_46) | G1: EMDR  G2: CBT, coping skills therapy (Biofeedback and general relaxation)  G3: WL | BDI  Mean (SD) G1 Pre-tx: 20.1 (7.5)  G1 Post-tx: 6.9 (5.9)  G1 3 mth FU: 8.6 (9.4)  G1 9 mth FU:6.6 (5.9)  G2 Pre-tx: 23.6 (10.8)  G2 Post-tx: 15.8 (12.5) G2 3 mth FU: 18.3 (11.7)  G2 9 mth FU:22.5 (12.1)  G3 Pre-tx: 24.0 (9.9)  G3 Post-tx: 23.5 (12.8)  Post & 3 mths  Group X Time, p<0.004  G1 vs. G3, p<0.01 (post)  G1 vs. G2, NS (3 months)  9 month FU p<0.00 (t-test)  STAI-State  G1 Pre-tx: 47.2 (9.4)  G1 Post-tx: 34.9 (9.0)  G1 3 mth FU:40.6 (4.9)  G2 Pre-tx: 58.2 (12.2)  G2 Post-tx: 46.3 (13.3)  G2 3 mth FU:47.7  G3 Pre-tx: 58.2 (10.5)  G3 Post-tx: 51.4 (17.8)  Post-tx & 3 mths  Group X Time, NS  9 mo FU: DataNR | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Carlson et al., 1998[46](#_ENREF_46) |  | STAI-Trait  Mean (SD)  G1 Pre-tx: 54.0 (9.9)  G1 Post-tx: 38.6 (9.7)  G1 3 mth FU: 41.9 (6.9)  G2 Pre-tx: 58.0 (9.1)  G2 Post-tx: 50.8 (10.7)  G2 3 mth FU: 51.8 (7.4)  G3 Pre-tx: 61.7 (10.6)  G3 Post-tx: 55.8 (11.2)  Group X Time, p<0.06  Post-tx  G1 vs. G3, p<0.001  G1 vs G2, p<0.01  3 month FU  G1 vs. G2, p<0.01 |  |  |  |

| Author, Year | Intervention Groups | Comorbid Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Chard et al., 2005[2](#_ENREF_2) | G1: CBT, cognitive processing therapy  CPT-SA  G2: WL | BDI-II Mean (SD) G1 Pre-tx: 24.43 (10.81) G1 Post-tx: 3.26 (4.75)  G2 Pre-tx: 24.52 (11.55) G2 Post-tx: 22.41 (12.57)  p<0.001 | NR | NR | NR |
| Church et al., 2013[155](#_ENREF_155) | G1: EFT, Emotional Freedom Techniques (brief exposure therapy combining cognitive and somatic elements, on PTSD and psychological distress symptoms in veterans) G2: WL | SA-45 GSI  Mean (SE)  G1 Pre-tx: 74.79 (1.4)  G1 Post-tx: 58.51 (1.9)  G2 Pre-tx: 72.39 (1.6)  G2 Post-tx: 69.98 (1.4)  Treatment X Time Interaction, p <0.0001  SA-45 PST  Mean (SE)  G1 Pre-tx: 72.74 (1.5)  G1 Post-tx: 57.61 (1.9)  G2 Pre-tx: 72.72 (1.5)  G2 Post-tx: 70.42 (1.3)  Treatment X Time Interaction, p <0.0001 | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Cloitre et al., 2002[37](#_ENREF_37) | G1: CBT, exposure-based therapy(STAIR)  G2: WL | BDI  Mean (SD) G1 Pre-tx:25 (10.6)  G1 Post-tx: 8 (7.8)  G2 Pre-tx:23 (9.0) G2 Post-tx: 22 (11.4)  p<0.01 (interaction)  STAI-S  Mean (SD) G1 Pre-tx:57 (9.6)  G1 Post-tx: 36 (8.6)  G2 Pre-tx: 53 (15.6)  G2 Post-tx: 55 (14.9)  p<0.01 (interaction) | NR | SAS-SR  Mean (SD) G1 Per-tx:2.44(0.29)  G1 Post-tx:2.06 (0.40)  G2 Pre-tx:2.57 (0.42)  G2 Post-tx: 2.47 (0.53)  p=0.02 (interaction) | NR |
| Cloitre et al., 2010[148](#_ENREF_148) | G1: CBT-Mixed  (STAIR) + PE  G2: CBT-Mixed  (STAIR) + Support (Skills Training)  G3: Support (Skills Training) + PE | STAI Mean (SD) G1 Pre-tx:50.4 (9.41)  G1 Post-tx:39.2 (9.92)  G1 3 mth FU:38.8 (9.90)  G1 6 mth FU:37.4 (10.72)  G2 Pre-tx: 48.2 (12.45)  G2 Post-tx: 42.9 (12.34)  G2 3 mth FU: 41.8 (13.53)  G2 6 mth FU:42.4 (12.66)  G3 Pre-tx: 50.2 (10.85) G3 Post-tx:41.1 (12.13)  G3 3 mth FU:51.8 (11.16)  G3 6 mth FU: 47.5 (12.66) |  |  |  |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Cloitre et al., 2010[148](#_ENREF_148)  (continued) |  | p<0.003 (interaction)  3 mth FU G1 vs. G3, p<0.001 6 mth FU  G1 vs. G3, p<0.003  BDI  Mean (SD) G1 Pre-tx: 18.8 (10.01)  G1 Post-tx: 8.9 (7.64)  G1 3 mth FU: 9.8 (9.96)  G1 6 mth FU: 7.9 (10.77)  G2 Pre-tx: 21.1 (8.80)  G2 Post-tx: 11.9 (8.54)  G2 3 mth FU: 12.0 (8.75)  G2 6 mth FU: 13.4 (8.84)  G3 Pre-tx: 22.1 (10.60)  G3 Post-tx: 12.9 (9.41)  G3 3 mth FU: 14.2 (10.09)  G3 6 mth FU: 13.6 (9.12)  No treatment or interaction effects obtained for BDI | NR | NR | NR |
| Coffey et al., 2016[140](#_ENREF_140) | G1: Modified PE+ Motivational enhancement therapy (met-ptsd),  G2: PE as described in G1 without MET, relaxation prior to PE therapy.  G3: HLS, relaxation prior to PE therapy | BDI-II  Mean (95% CI) G1 Pre-tx: 32.40 (29.21, 35.69)  G1 Post-tx: 10.78 (7.07, 14.50)  G1 3month followup: 14.34 (9.82, 18.87)  G1 6month followup: 13.39 (8.49, 18.30)  G2 Pre-tx: 29.49 (26.48, 32.49)  G2 Post-tx: 7.08 (3.49, 10.66)\* |  |  |  |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Coffey et al., 2016[140](#_ENREF_140)  (continued) |  | G2 3 month followup: 10.21 (5.90, 14.51)\*  G2 6 month: 6.60 (2.16, 11.19)\*  G3 Pre-tx: 29.80 (26.61, 32.90)  G3 Post-tx: 13.33 (9.89, 16.77)  G3 3 month: 16.84 (12.94, 20.73)  G3 6 month: 13.59 (8.97, 18.22) \*Denotes significant improvement over HLS at alpha = .05  Treatment x time effect, post-tx: X2 = 5.16, p = 0.08  Treatment x time effect, followup: X2 = 1.03, p = 0.91  Cohen's d as compared with G3: G1 Post-tx: 0.22 G2 Post-tx: 0.26 G1 3 month followup: 0.18 G2 3 month followup: 0.48 G1 6 month followup: 0.006 G1 6 month followup: 0.46 |  |  |  |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Coffey et al., 2016[140](#_ENREF_140)  (continued) |  | Alcohol PDA  Mean (95% CI) G1 Pre-tx: 48.70 (41.82 to 55.57)  G1 3 month followup: 92.46 (85.66 to 99.25)  G1 6 month followup: 85.73 (78.94 to 92.52)  G2 Pre-tx: 46.13 (39.04 to 52.61)  G2 3 month followup: 97.32 (90.76 to 103.87)  G2 6 month followup: 94.49 (87.94 to 101.05)  G3 Pre-tx: 52.23 (45.53 to 59.03)  G3 3 month followup: 97.08 (90.28 to 103.88)  G3 6 month followup: 93.58 (86.78 to 100.37)  Treatment x time effect, 3-month followup: X2 = 1.51, p = 0.47  Treatment x time effect, 6 month followup: X2 = 1.11, p = 0.58  Cohen's d as compared with G3: G1 3 month followup: 0.21 G2 3 month followup: 0.01 G1 6 month followup: 0.36  G2 6 month followup: 0.04 | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Coffey et al., 2016[140](#_ENREF_140)  (continued) |  | Drug PDA  Mean (95% CI)  G1 Pre-tx: 45.47 (38.50 to 52.43)  G1 3month followup: 93.37 (86.49 to 100.26)  G1 6month followup: 91.97 (85.08 to 98.85)  G2 Pre-tx: 53.44 (46.87 to 60.01)  G2 3 month followup: 97.52 (90.87 to 104.16)  G2 6 month: 96.94 (90.87 to 104.16)  G3 Pre-tx: 59.59 (52.71 to 66.48)  G3 3 month: 97.94 (91.06 to 104.83)  G3 6 month: 91.70 (84.82 to 98.59)  Treatment x time effect, 3-month followup: X2 = 0.92, p = 0.63  Treatment x time effect, 6 month followup: X2 = 2.20, p = 0.33  Cohen's d as compared with G3:  G1 3 month followup: 0.24  G2 3 month followup: 0.02  G1 6 month followup: 0.21  G1 6 month followup: 0.02 |  |  |  |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Connor et al., 1999[170](#_ENREF_170)  Meltzer-Brody et al., 2000[171](#_ENREF_171) | G1: Fluoxetine  10 to 60mg/day  G2: Placebo | NR | NR | SDS Week 12 difference (Baseline - Endpoint)(95% CI) G1 vs. G2 Difference: 6.2 (1.4 to 11.0), p<0.05  CHEF criterion of response Week 12 difference (Baseline - Endpoint)(95% CI) G1 vs. G2 Difference: 0.37 (0.17 to 0.57), p<0.001 | NR |
| Cook et al., 2010[156](#_ENREF_156) | G1: CBT, exposure-based therapy  G2: Psychoeducation | BDI  Mean (SD)  G1 Pre-tx: 26.85 (11.82)  G1 at 1 mth: 24.16 (13.35)  G1 at 3 mths: 24.80 (13.14)  G1 at 6 mths: 25.02 (13.30)  G2 Pre-tx: 23.51 (11.92) G2 at 1 month: 22.31 (12.76)  G2 at 3 mths:23.76 (12.76)  G2 at 6 mths: 23.37 (12.34) Interactions, NS | SF-36 Mental  Mean (SD)  G1 Pre-tx:29.69 (9.08)  G1 at 1 mth:32.33 (10.63)  G1 at 3 mths: 30.98 (9.33)  G1 at 6 mths:32.15 (8.99)  G2 Pre-tx:34.52 (12.06)  G2 at 1 mth:32.84 (9.75)  G2 at 3mths: 34.00 (10.35)  G2 at 6 mths: 34.78 (10.87) Interactions, NS |  | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Cook et al., 2010[156](#_ENREF_156) (continued) |  |  | SF-36 Physical Component  Mean (SD)  G1 Pre-tx: 37.17 (9.21)  G1 1 mth:39.48 (10.19)  G1 at 3 mths: 37.72 (9.57)  G1 at 6mths: 35.80 (9.64)   G2 Pre-tx: 38.53 (9.64)  G2 Post-tx:36.84 (10.34)  G2 at 3 mths: 35.96 (11.97)  G2 at 6 mths: 37.21 (11.23)  Interactions, NS |  |  |
| Cottraux, 2008[31](#_ENREF_31) | G1: CBT-mixed  (Exposure in imagination or in vivo and cognitive therapy)  G2: Supportive Control | HAM-A Post-tx (ITT analysis)  G1 Mean Change from Baseline (SD): -11 (9) G2 Mean Change from Baseline (SD): -5.7 (8) Group effect, p=0.028  Interaction, p=NS  52 Weeks  G1 Mean Change from Baseline (sd): -10.04 (11.18),  G2 Mean Change from Baseline (sd): -8.79 (10.15),  Interaction, p=0.73 | Marks' Quality of Life Scale ITT analysis = NR  Post-tx (completer analysis) G1 Mean Change from Baseline (SD): -6.66 (8.13) G2 Mean Change from Baseline (SD): -9.60 (7.98) p=0.26 | Fear Questionnaire, Global Phobic Disability Subscale: ITT analysis = NR  Post-tx (completer analysis) POST-TREATMENT G1 Mean Change from Baseline (SD): -2.14 (2.75) G2 Mean Change from Baseline (SDI): -2.00 (2.69)  p=0.86 | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Cottraux, 2008[31](#_ENREF_31)  (continued) |  | 104 Weeks  G1 Mean Change from Baseline (sd): -12.56 (11.29), p=NR  G2 Mean Change from Baseline (sd): -17.00 (7.19), p=NR  Interaction, p=0.30  Depression, BDI short form  ITT = NR  Completer Analysis (Post-tx):  G1 Mean Change from Baseline (sd): -5.44 (6.15)  G2 Mean Change from Baseline (sd): -4.66 (6.95),  Interaction, p=0.70  52 WEEKS  G1 Mean Change from Baseline (sd): -4.33(5.65),  G2 Mean Change from Baseline (sd): -4.07 (5.80),  Interaction, p=0.89  104 WEEKS:  G1 Mean Change from Baseline (sd): -5.87 (6.66), p=NR  G2 Mean Change from Baseline: -6.22 (5.84), p=NR  Interaction, p=0.89 |  |  |  |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Cottraux, 2008[31](#_ENREF_31) (continued) |  |  | 52 Weeks G1 Mean Change from Baseline (SD): -9.42 (9.36), p=NR G2 Mean Change from Baseline (SD): -7.64 (9.12), p=NR Interaction, p=0.57  104 Weeks G1 Mean Change from Baseline (SD): -10.00 (7.65), p=NR G2 Mean Change from Baseline (SD): -12.66 (8.23), p=NR Interaction, p=0.42 | 52 Weeks G1 Mean Change from Baseline (SD): -2.54 (2.90), p=NR G2 Mean Change from Baseline (SDI): -1.00 (2.48), p=NR Interaction, p=0.11  104 Weeks G1 Mean Change from Baseline (SD): -3.52 (2.79), p=NR G2 Mean Change from Baseline (SDI): -2.33 (2.82), p=NR Interaction, p=0.44 |  |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Davidson et al., 2001[68](#_ENREF_68) | G1: Sertraline  50 to 200 mg/day  G2: Placebo | HAM-D Change from Baseline to Endpoint (SD)  G1: -7.7 (1.0) G2: -6.3 (1.0) p=0.33 (t-test)  HAM-A Change from Baseline to Endpoint (SD)  G1: -7.8 (0.8) G2: -6.4 (0.9) p=0.26 (t-test) | NR | NR | NR |
| Davidson et al., 2003[184](#_ENREF_184) | G1: Mirtazapine  15 to 45 mg/day  G2: Placebo | HADS-D  Mean (SD) G1 Pre-tx: 10.2 (6.1) G1 Post-tx: 8.0 (6.0)  G2 Pre-tx: 13.5 (4.3) G2 Post-tx: 13.0 (3.7)  Treatment effect, p=0.08  HADS-A G1 Pre-tx: 11.8 (5.0) G1 Post-tx: 9.0 (5.8)  G2 Pre-tx: 15.0 (3.3) G2 Post-tx 13.8 (3.7)  Treatment effect, p<0.05 | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Davidson et al., 2006[69](#_ENREF_69) | G1: Venlafaxine  75 to 300mg/day  G2: Sertraline  50 to 200mg/day  G3: Placebo | HAM-D  Mean Within-group difference (95% CI) G1: -7.09(-8.13 to -6.05)  G2: -6.42 (-7.48 to - 5.37) G3: -5.54 (-6.58 to -4.50)  Between group p-values based on pairwise comparisons from the analysis of variance model using baseline adjusted values G1 vs. G3: 0.039 G2 vs. G3: 0.244 G1 vs. G2: 0.379 | Q-LES-Q-SF  Mean Within-group difference (95% CI) G1: 11.54 (9.73 to 13.35)  G2: 11.17 (9.30 to 13.04) G3: 8.75 (6.94 to 10.56)  Between group p-values based on pairwise comparisons from the analysis of covariance model using baseline adjusted values G1 vs. G3: 0.033 G2 vs. G3: 0.068 G1 vs. G2: 0.782 | GAF Mean Within-group difference (95% CI) G1: 14.16(12.16 to 16.16)  G2: 13.63 (11.57 to 15.70) G3: 11.41 (9.32 to 13.49)  Between group p-values based on pairwise comparisons from the analysis of covariance model using baseline adjusted values G1 vs. G3: 0.062 G2 vs. G3: 0.136 G1 vs. G2: 0.720  SDS  Mean Within-group difference (95% CI)  G1: -8.54 (-9.78 to -7.29)  G2:-8.17 (-9.43 to -6.90)  G3: -6.52 (-7.76 to -5.29)  Between group p-values based on pairwise comparisons from the analysis of covariance model using baseline adjusted values  G1 vs. G3: 0.025  G2 vs. G3: 0.068  G1 vs. G2: 0.683 | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Davidson et al., 2006[73](#_ENREF_73) | G1: Venlafaxine  37.5 to 300 mg/day  G2: Placebo | HAM-D Between Group Mean Difference -1.4, p=0.007 | Q-LES-Q-SF  Between Group Mean Difference 3.7, p=0.007 | SDS  Between Group Mean Difference -2.0, p=0.03  GAF  Between Group Mean Difference 3.3, p=0.03 |  |
| Davidson et al., 2007[166](#_ENREF_166) | G1: Tiagabine  4 to16mg/day  G2: Placebo | NR | NR | SDS  Change from baseline (SD) G1: -5.5 (7.0) G2: -5.9 (7.7) p=0.74 | NR |
| Davis et al., 2008[164](#_ENREF_164) | G1: Divalproex  1000 to 3000 mg/day  G2: Placebo | MADRS  Mean (SD) G1 Pre-tx: 27.3 (8.5)  G1 Post-tx:22.2 (10.6)  G2 Pre-tx: 28.5 (7.1)  G2 Post-tx: 24.0 (10.3)  Diff b/t groups, p=NS  HAM-A  Mean (SD) G1 Pre-tx:24.1 (10.1)  G1 Post-tx:19.4 (9.1)  G2 Pre-tx: 22.8 (8.5)  G2 Post-tx::20.1 (10.7)  Diff b/t groups, p=NS | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Ehlers et al., 2003[5](#_ENREF_5) | G1: CT  G2: Self-help booklet based on principles of CBT  G3: Repeated assessments | BDI  Mean (SD)  G1 Pre-tx: 18.8 (6.7)  G1 3 mth FU: 7.3 (6.3)  G1 9 mth FU: 6.5(7.0)  G2 Pre-tx: 22.9 (9.2)  G2 3 mth FU: 16.1 (6.6)  G2 9 mth FU: 15.2 (6.9)  G3 Pre-tx: 22.7 (8.9)  G3 3 mth FU: 17.1 (9.6)  G3 9 mth FU: 12.0 (10.0)  3 mth FU  Overall: p<0.001  G1 vs. G2, p<0.001  G1 vs. G3, p<0.001  9 mth FU  Overall: p<0.001  G1 vs. G2, p<0.001  G1 vs. G3, p=0.02  BAI Mean (SD)  G1 Pre-tx: 21.6 (7.9) G1 3 mth FU: 6.0 (5.8)  G1 9 mth FU: 5.8 (4.9)  G2 Pre-tx: 22.2 (9.9)  G2 3 mth FU: 14.2 (8.9)  G2 9 mth FU: 14.0 (8.6)  G3 Pre-tx: 24.4 (7.4)  G3 3 mth FU: 15.7 (10.4)  G3 9 mth FU: 12.6 (8.6) | NR | SDS Mean (SD)  G1 Pre-tx: 5.9 (2.4)  G1 3 mth FU: 2.3 (2.8)  G1 9 mth FU: 1.8 (2.5)  G2 Pre-tx: 6.3 (2.0) G2 3 mth FU: 4.3 (2.5)  G2 9 mth FU: 3.7 (2.2)  G3 Pre-tx: 6.1 (1.9)  G3 3 mth FU: 4.2 (1.9)  G3 9 mth FU: 3.2 (2.7)  3 mth FU  Overall: p<0.001  G1 vs.G2, p=0.001  G1 vs. G3, p<0.001  9 mth FU Overall: p=0.003  G1 vs. G2, p=0.001  G1 vs. G3, p= 0.007 | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Ehlers et al., 2003[5](#_ENREF_5)  (continued) |  | 3 mth FU  Overall: p<0.001  G1 v.s G2: p<0.001  G1 vs. G3: p<0.001  9 mth FU  Overall: p<0.001  G1 vs. G2, p<0.001  G1 vs. G3, p<0.001 |  |  |  |
| Ehlers et al., 2005[8](#_ENREF_8) | G1: CBT-mixed  Cognitive therapy including restructuring and exposure  G2: WL | BDI Mean (SD) G1 Pre-tx: 23.7 (9.0) G1 Post-tx: 10.6 (8.6) G1 6 mth FU: 11.2 (9.6)  G2 Pre-tx: 23.2 (8.0) G2 Post-tx: 19.3 (7.2)  G1 vs. G2, p=0.003  G1 Changes, p<0.0005  G2 Changes, p=0.025  BAI Mean (SD) G1 Pre-tx: 24.1 (11.1) G1 Post-tx: 8.2 (10.8) G1 6 mth FU: 7.5 (9.7)  G2 Pre-tx: 19.2 (7.2) G2 Post-tx: 21.2 (11.2)  G1 vs. G2, p<0.0005  G1 Changes, p<0.0005  G2 Changes, NS | NR | SDS Mean (SD) G1 Pre-tx: 7.6 (1.9) G1 Post-tx: 3.0 (2.6) G1 6 mth FU: 3.0 (2.6)   G2 Pre-tx: 6.7 (1.9) G2 Post-tx: 6.3 (1.8)  G1 vs. G2, p<0.0005  G1 Changes, p<0.0005  G2 Changes, NS | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Ehlers et al., 2014[9](#_ENREF_9) | G1: Intensive CT (standard CT delivered over a much shorter period)  G2: Standard CT  G3: Supportive Therapy  G4: WL | BDI (ITT)  Mean (SD)  G1 Pre-tx: 23.93 (9.86)  G1 6 weeks: 14.34 (9.30)  G1 Post-tx:12.10 (9.97)  G1 Followup 1 (27 weeks): 12.03 (11.25)  G1 Followup 2 (40 weeks):12.84(12.54)  Within-group pre-post effect, d= 1.19  G2 Pre-tx: 21.90 (10.77)  G2 6 weeks: 13.39 (10.70)  G2 Post-tx: 11.07 (11.80)  G2 Followup 1 (27 weeks): 10.54 (12.70)  G2 Followup 2 (40 weeks): 9.44 (12.18)  Within-group pre-post effect, d = 0.96  G3 Pre-tx: 26.18 (10.68)  G3 6 weeks: 19.79 (12.42)  G3 Post-tx: 17.00 (12.82)  G3 Followup 1 (27 weeks): 16.29(12.10)  G3 Followup 2 (40 weeks): 18.60 (14.05)  Within-group pre-post effect, d = 0.78  G4 Pre-tx: 23.47 (8.96)  G4 6 weeks: 21.26 (8.06)  G4 Post-tx: 20.85 (10.02)  Within-group pre-post effect, d = 0.28 | Quality of Life Enjoyment an Satisfaction Questionnaire (ITT)  Mean (SD)  G1 Pre-tx: 36.93 (12.84)  G1 6 weeks: 49.54 (17.23)  G1 Post-tx:52.67 (20.21)  G1 Followup 1 (27 weeks): 58.10 (22.78)  G1 Followup 2 (40 weeks):54.57(20.74)  Within-group pre-post effect, d= 0.93  G2 Pre-tx: 39.36 (21.87)  G2 6 weeks: 57.49 (20.82)  G2 Post-tx: 62.93 (21.70)  G2 Followup 1 (27 weeks): 60.43 (23.31)  G2 Followup 2 (40 weeks): 65.11 (22.46)  Within-group pre-post effect, d = 1.08  G3 Pre-tx: 38.78 (18.40)  G3 6 weeks: 44.86 (25.25)  G3 Post-tx: 49.22 (24.97)  G3 Followup 1 (27 weeks): 49.61(25.67) | SDS (ITT)  Mean (SD)  G1 Pre-tx: 20.48 (5.55)  G1 6 weeks: 10.72 (7.51)  G1 Post-tx:9.30 (8.20)  G1 Followup 1 (27 weeks): 10.61 (8.80)  G1 Followup 2 (40 weeks):9.72(9.22)  Within-group pre-post effect, d= 1.60  G2 Pre-tx: 21.39 (5.11)  G2 6 weeks: 14.02 (9.35)  G2 Post-tx: 10.02(9.76)  G2 Followup 1 (27 weeks): 8.68 (9.50)  G2 Followup 2 (40 weeks): 9.37 (10.07)  Within-group pre-post effect, d = 1.50  G3 Pre-tx: 19.65 (6.97)  G3 6 weeks: 16.60 (7.90)  G3 Post-tx: 14.28 (9.09)  G3 Followup 1 (27 weeks): 13.67(9.86)  G3 Followup 2 (40 weeks): 14.47 (11.35  Within-group pre-post effect, d = 0.66  G4 Pre-tx: 17.28 (7.74)  G4 6 weeks: 17.22 (6.67)  G4 Post-tx: 17.20 (6.38)  Within-group pre-post effect, d = 0.01 | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Ehlers et al., 2014[9](#_ENREF_9)  (continued) |  | Comparison of Treatment with Waitlist  Treatment by time Interactions, F=5.16, df=3, 122.20, p<0.002  Between group effect sizes  Adjusted Difference (95% CI)  G1 vs. G4: 9.04 (4.26 to 13.81), p<0.001, d = 0.97  G2 vs. G4:8.81 (4.06 to 13.55), p<0.001, d= 0.95  G1 vs. G3: 3.49(-1.30 to 8.28), NS, d=0.37  G2 vs G3: 3.26 (-1.50 to 8.05), NS, d = 0.35  Interaction between condition and Linear time effects: F=0.79, df=2, 213.98, p > 0.23  BAI (ITT)  Mean (SD)  G1 Pre-tx: 26.23 (13.12)  G1 6 weeks: 13.55 (12.16)  G1 Post-tx:11.57 (11.94) Followup 1 (27 weeks): 10.37 (11.59)  G1 Followup 2 (40 weeks):11.85(13.35)  Within-group pre-post effect, d= 1.17  G2 Pre-tx: 28.42 (14.17)  G2 6 weeks: 13.88(14.01)  G2 Post-tx: 9.24 (12.09)  G2 Followup 1 (27 weeks): 9.63 (13.71) | G3 Followup 2 (40 weeks): 50.38 (25.53)  Within-group pre-post effect, d = 0.48  G4 Pre-tx: 45.68 (20.98)  G4 6 weeks: 41.74 (15.13)  G4 Post-tx: 46.75 (19.00)  Within-group pre-post effect, d = 0.05  Comparison of Treatment with Waitlist  Treatment by time Interactions, F=6.96, df=3, 106.85, p<0.002  Between group effect sizes  Adjusted Difference (95% CI)  G1 vs. G4: -12.43 (-21.28 to -3.58), p<0.01, d = 0.73  G2 vs. G4:-20.67 (-29.39 to -11.95), p<0.001, d= 1.21  G1 vs. G3: -4.45(-13.17 to 4.28), NS, d=0.26  G2 vs G3: -12.69 (-21.33 to -4.04), p<0.01, d = 0.74 | Comparison of Treatment with Waitlist  Treatment by time Interactions, F=14.01, df=3, 109.86, p<0.002  Between group effect sizes  Adjusted Difference (95% CI)  G1 vs. G4: 9.96(6.10 to 13.81), p<0.001, d = 1.33  G2 vs. G4: 9.82 (5.95 to 13.68), p<0.001, d= 1.30  G1 vs. G3: 5.51(1.71 to 9.31), p<0.01, d=0.74  G2 vs G3: 5.37 (1.59 to 9.15), p<0.01, d = 0.72  Interaction between condition and Linear time effects: F=7.45, df=2, 220.14, p = 0.001 |  |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Ehlers et al., 2014[9](#_ENREF_9)  (continued) |  | G2 Followup 2 (40 weeks): 9.00 (12.61)  Within-group pre-post effect, d = 1.46  G3 Pre-tx: 25.12 (11.31)  G3 6 weeks: 17.01 (13.30)  G3 Post-tx: 16.35 (14.56)  G3 Followup 1 (27 weeks): 15.50(13.74)  G3 Followup 2 (40 weeks): 15.99 (16.15)  Within-group pre-post effect, d = 0.67  G4 Pre-tx: 23.57 (9.12)  G4 6 weeks: 23.26 (10.88)  G4 Post-tx: 22.13 (10.59)  Within-group pre-post effect, d = 0.15  Comparison of Treatment with Waitlist  Treatment by time Interactions, F=13.57, df=3, 106.85, p<0.002  Between group effect sizes  Adjusted Difference (95% CI)  G1 vs. G4: 11.98 (6.54 to 17.43), p<0.001, d = 1.13  G2 vs. G4:15.58 (10.04 to 20.91), p<0.001, d= 1.45  G1 vs. G3: 5.37(0.06 to 10.80), p <0.05, d=0.51  G2 vs G3: 8.86 (3.46 to 14.27), p<0.01, d = 0.83 | Interaction between condition and Linear time effects: F=3.27, df=2, 231.98, p = 0.04 |  |  |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Ehlers et al., 2014[9](#_ENREF_9)  (continued) |  | Interaction between condition and Linear time effects: F=5.40, df=2, 176.80, p = 0.005 |  |  |  |
| Engel et al., 2015[26](#_ENREF_26) | G1: DESTRESS-PC (Delivery of Self Training and Education for Stressful Situations-Primary Care), a nurse guided online CBT and SIT  G2: Optimized UC, usual primary care PTSD treatment augmented with low intensity care management, feedback to the primary care provider, and training of the clinic providers in management of PTSD. | PHQ-8 (Major Depression)  Mean (SD)  G1 Pre-tx: 13.53 (5.43)  G1 Post-tx (6 weeks): 11.00 (6.65)  G1 Post-tx (12 weeks): 9.66 (7.04)  G1 Post-tx (18 weeks): 10.23 (7.01)  G2 Pre-tx: 11.67 (4.65)  G2 Post-tx (6 weeks): 10.24 (5.12)  G2 Post-tx (12 weeks): 10.40 (6.77)  G2 Post-tx (18 weeks): 8.96 (5.62)  Treatment by time interaction, F(3, 186)=2.17, p=0.093  PHQ-15 (Somatic symptoms)Mean (SD)  G1 Pre-tx: 13.25 (5.64)  G1 Post-tx (6 weeks): 11.90 (5.63)  G1 Post-tx (12 weeks): 11.37 (6.70)  G1 Post-tx (18 weeks): 11.38 (6.16) | SF-36  Means NR  Interaction terms, NS | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Engel et al., 2015[26](#_ENREF_26)  (continued) |  | G2 Pre-tx: 13.31 (5.04)  G2 Post-tx (6 weeks): 11.86 (5.18)  G2 Post-tx (12 weeks): 12.16 (6.80)  G2 Post-tx (18 weeks): 10.79 (6.48)  Interaction terms, NS |  |  |  |
| Fecteau et al., 1999[38](#_ENREF_38) | G1: CBT-mixed  (Coping skills, exposure-therapy, and cognitive restructuring)  G2: WL | BAI  Mean (SD)  G1 Pre-tx: 30.6 (7.4)  G1 Post-tx: 15.8 (13.8)  G2 Pre-tx: 34.8 (15.8)  G2 Post-tx: 32.0 (13.3)  Group effect, p-value <0.05  Follow up for G1 Only  BAI  G1 Pre-tx: 30.6 (7.4)  G1 Post-tx: 15.8 (13.8)  G1 3 mth FU: 16.9 (13.8)  G1 6 mth FU: 16.8 (11.8)  Change at 3 mths, p<0.05 (n = 10)  Change at 6 mths, p<0.01 (n = 8)  BDI  Mean (SD)  G1 Pre-tx: 26.3 (9.8)  G1 Post-tx: 20.1 (17.1)  G2 Pre-tx: 27.9 (10.5)  G2 Post-tx: 24.7 (8.1) | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Fecteau et al., 1999[38](#_ENREF_38)  (continued) |  | Group effect, NS  Follow up for G1 Only  BDI  G1 Pre-tx: 26.3 (9.8)  G1 Post-tx: 20.1 (17.1)  G1 3 mth FU: 19.6 (15.6)  G1 6 mth FU: 15.9 (11.0)\*\*  Change at 3 mths, NS (n = 10)  Change at 6 mths, NS (n = 8) |  |  |  |
| Foa et al., 1999[14](#_ENREF_14)  Zoellner et al., 1999[134](#_ENREF_134) | G1: CBT, exposure-based therapy (PE)  G2: CBT, coping skills therapy  SIT  G3: CBT-mixed  Combined treatment (PE and SIT)  G4: WL | BDI  Mean (SD) G1 Pre-tx: 17.58 (11.29) G1 Post-tx: 5.75 (4.77) G1 3 mth FU: 8.02 (6.77) G1 6 mth FU: 6.85 (5.61)  G1 12 mth FU: 6.15 (7.73)  G2 Pre-tx: 21.73 (11.02) G2 Post-tx: 10.05 (8.06) G2 3 mth FU: 14.58 (12.16) G2 6 mth FU: 13.54 (12.51) G2 12 mth FU: 11.92 (14.48)  G3 Pre-tx: 21.36 (10.51) G3 Post-tx: 10.49 (9.90) G3 3 mth FU: 13.65 (10.53) G3 6 mth FU: 10.00 (9.46) G3 12 mth FU: 11.88 (9.92)  G4 Pre-tx: 25.21 (11.20) G4 Post-tx: 22.10 (14.97)  Main Effect, p<0.01  G1 vs. G4, p<0.001  G2 vs. G4, p<0.05  G3 vs. G4, p<0.05 | NR | Social Adjustment Scale - Global Mean (SD) G1 Pre-tx: 3.73 (0.83) G1 Post-tx: 2.45 (0.60) G1 3 mth FU: 2.58 (0.69) G1 6 mth FU: 2.33 (0.84) G1 12 mth FU: 2.69 (0.87)  G2 Pre-tx: 3.79 (1.23) G2 Post-tx: 2.68 (1.00) G2 3 mth FU: 3.00 (1.37) G2 6 mth FU: 2.83 (1.10) G2 12 mth FU: 3.00 (1.30)  G3 Pre-tx: 4.00 (1.11) G3 Post-tx: 2.95 (1.33) G3 3 mth FU: 3.37 (1.46) G3 6 mth FU: 2.94 (1.55) G3 12 mth FU: 3.13 (2.03)  G4 Pre-tx: 3.93 (1.16) G4 Post-tx: 3.73 (1.10)  Treatment Effect, p<0.05  G1 vs. G4, p<0.01  G2 vs. G4, p=0.08  G3 vs. G4, p=0.09  Active treatments did not differ from one another, p=0.14 | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Foa et al., 1999[14](#_ENREF_14)  Zoellner et al., 1999[134](#_ENREF_134)  (continued) |  | G1 vs. G3, p<0.025  G1 vs. G2, p=0.06  STAI-State Mean (SD) G1 Pre-tx: 49.95 (13.70) G1 Post-tx: 32.43 (10.93) G1 3 mth FU: 37.16 (11.80) G1 6 mth FU: 34.95 (11.45) G1 12 mth FU: 34.84 (12.43)  G2 Pre-tx: 51.50 (13.37) G2 Post-tx: 39.07 (11.55) G2 3 mth FU: 41.26 (14.02) G2 6 mth FU: 43.33 (17.01) G2 12 mth FU: 42.46 (16.98)  G3 Pre-tx: 50.66 (15.37) G3 Post-tx: 40.55 (15.41) G3 3 mth FU: 43.74 (15.27) G3 6 mth FU: 41.12 (14.77) G3 12 mth FU: 38.75 (13.29)  G4 Pre-tx: 51.44 (12.60) G4 Post-tx: 50.40 (13.80)  Main Effect, p<0.01  G1 vs. G4, p<0.001  G2 vs. G4, p=0.11  G3 vs. G4, p=0.14  G2 vs. G3, NS  G1 vs. G2, p<0.025  G1 vs. G3, p<0.01 |  |  |  |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Foa et al., 2005[12](#_ENREF_12) | G1: CBT, exposure-based therapy(PE)  G2: CBT-mixed  (PE plus CR)  G3: WL | BDI Mean (SD) G1 Pre-tx: 26.1 (9.9) G1 Post-tx: 14.6 (13.8)  G2 Pre-tx: 23.4 (9.3) G2 Post-tx: 13.8 (12.9)  G3 Pre-tx: 23.6 (10.3) G3 Post-tx: 21.0 (10.7)    Group X Time interaction, p<0.001  G1 vs. G3, p<0.05  G2 vs. G3, p<0.05  G1 vs. G2, ns | NR | Social Adjustment Scale - Work Mean (SD) G1 Pre-tx: 3.4 (1.2) G1 Post-tx: 2.8 (1.4)  G2 Pre-tx: 3.2 (1.2) G2 Post-tx: 2.7 (1.4)  G3 Pre-tx: 3.4 (1.5) G3 Post-tx: 3.5 (1.3)  Group X Time interaction, p=0.059  Social Adjustment Scale-Social Mean (SD) G1 Pre-tx: 4.1 (1.0) G1 Post-tx: 3.5 (1.3)  G2 Pre-tx: 4.0 (1.0) G2 Post-tx: 3.3 (1.2)  G3 Pre-tx: 4.0 (1.2) G3 Post-tx: 3.8 (1.1)  Group X Time interaction, ns | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Fonzo et al., 2017[137](#_ENREF_137)  Fonzo et al., 2017[21](#_ENREF_21) | G1: PE  G2: WL | BDI-II  Mean (SD)  G1 Pre-tx: 23.69 (8.68)  G1 Post-tx: 9.69 (7.77)  G2 Pre-tx: 23.17 (8.60)  G2 Post-tx: 17.87 (9.27)  Group X Time interaction, p=0.016 | WHO QOL of BREF  Mean (SD)  Physical Health  G1 Pre-tx: 12.46 (2.99)  G1 Post-tx: 14.63 (3.29)  G2 Pre-tx: 12.43 (3.11)  G2 Post-tx: 12.65 (3.19)  Group X Time interaction, p=0.039  Psychological Health  G1 Pre-tx: 10.04 (2.29)  G1 Post-tx: 13.19 (2.59)  G2 Pre-tx: 10.83 (2.34)  G2 Post-tx: 11.94 (2.52)  Group X Time interaction, p=0.033  Social Relationships  G1 Pre-tx: 9.71 (4.06)  G1 Post-tx: 11.83 (3.20)  G2 Pre-tx: 9.29(3.51)  G2 Post-tx: 10.73 (3.20)  Group X Time interaction, p=0.35  Environmental  G1 Pre-tx: 12.30 (3.48)  G1 Post-tx: 14.59 (2.42)  G2 Pre-tx: 12.79 (3.37)  G2 Post-tx: 13.57 (2.99)  Group X Time interaction, p=0.22 | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Forbes et al., 2012[4](#_ENREF_4) | G1: CBT, CPT  G2: TAU | BDI-II  Mean (SD)  G1 Pre-tx: 26.33 (11.38)  G1 Post-tx:15.91 (11.97)  G1 FU: 14.77 (12.86)  G2 Pre-tx: 24.78 (11.99)  G2 Post-tx: 20.83 (11.83)  G2 FU: 19.11 (10.15)  Change over time  Post-tx, p=0.054  FU, p=0.785  STAI-Trait  Mean (SD)  G1 Pre-tx: 59.97 (13.52)  G1 Post-tx: 44.59 (13.12)  G1 FU: 43.59 (11.49)  G2 Pre-tx: 50.29 (9.94)  G2 Post-tx: 48.31 (12.75)  G2 FU: 47.26 (16.17)  Change over time  Post-tx, p=0.018  FU, p=0.917 | Abbreviated Dyadic Adjustment Scale (ADAS)  Mean (SD)  G1 Pre-tx: 25.84 (6.95)  G1 Post-tx:27.41 (7.72)  G1 FU: 25.81 (6.80)  G2 Pre-tx: 28.73 (5.13)  G2 Post-tx:26.15 (6.34)  G2 FU: 27.98 (6.98)  Change over time  Post-tx, p=0.014  FU, p=0.025  World Health Organization Quality of Life Scale (WHO-QOL)  WHOQOL-Physical  Mean (SD)  G1 Pre-tx: 19.68 (5.23)  G1 Post-tx:21.23 (5.00)  G1 FU:19.81 (5.38)  G2 Pre-tx: 20.73 (4.69)  G2 Post-tx:22.20 (4.90)  G2 FU:20.39 (4.70) | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Forbes et al., 2012[4](#_ENREF_4)  (continued) |  |  | Change over time  Post-tx, p=0.911  FU, p=0.453  WHOQOL-Psychological  Mean (SD)  G1 Pre-tx: 15.70 (4.34)  G1 Post-tx:18.22 (4.59)  G1 FU: 18.40 (4.66)  G2 Pre-tx: 15.54 (3.56)  G2 Post-tx: 16.23 (4.27)  G2 FU: 16.35 (4.88)  Change over time  Post-tx, p=0.093  FU, p=0.955  WHOQOL-Social  Mean (SD)  G1 Pre-tx: 7.77 (2.78)  G1 Post-tx: 8.43 (3.36)  G1 FU: 8.97 (3.12)  G2 Pre-tx: 8.46 (2.83)  G2 Post-tx: 8.29 (2.20)  G2 FU: 8.00 (2.38) |  |  |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Forbes et al., 2012[4](#_ENREF_4)  (continued) |  |  | Change over time  Post-tx, p=0.152  FU, p=0.197  WHOQOL-Environmental  Mean (SD)  G1 Pre-tx: 27.50 (4.53)  G1 Post-tx: 28.73 (3.97)  G1 FU: 28.16 (4.29)  G2 Pre-tx: 29.07 (4.80)  G2 Post-tx:28.40 (4.89)  G2 FU: 28.14 (5.51)  Change over time  Post-tx, p=0.016  FU, p=0.738 |  |  |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Ford et al., 2011[59](#_ENREF_59) | G1: Trauma Affect Regulation: Guide for Education and Therapy (TARGET)  G2: PCT  G3: WL | BDI  Mean (SD)  G1 Pre-tx:16.0 (10.8)  G1 Post-tx:11.6 (10.9)  G2 Pre-tx:17.8 (10.2)  G2 Post-tx:11.9 (10.1)  G3 Pre-tx:17.8 (10.2)  G3 Post-tx:11.9 (10.1)  Group X Time Effect, p<0.01  STAI  Mean (SD)  G1 Pre-tx: 38.1 (13.0)  G1 Post-tx: 31.4 (11.3)  G2 Pre-tx:41.6 (13.0)  G2 Post-tx:37.4 (13.3)  G3 Pre-tx:43.0 (10.9)  G3 Post-tx:42.6 (12.9)  Group X Time Effect, p=0.19 | NR | NR | NR |
| Ford et al., 2011[60](#_ENREF_60) | G1: Trauma Affect Regulation:  Guide for Education and  Therapy (TARGET),  G2: SGT | TSI Dissociation Symptoms  Mean (SD)  G1 Pre-tx: 14.5 (6.5)  G1 Post-tx: 14.1 (6.4)  G2 Pre-tx: 12.0 (6.0)  G2 Post-tx: 9.1 (5.5)  Treatment X Time Interaction at post-tx, F= 1.6, NS, d = -0.26  TSI Sexual Concerns  Mean (SD)  G1 Pre-tx: 9.6 (6.0)  G1 Post-tx: 8.2 (7.3) | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Ford et al., 2011[60](#_ENREF_60)  (continued) |  | G2 Pre-tx: 6.1 (5.2)  G2 Post-tx: 5.5 (4.7)  Treatment X Time Interaction at post-tx, F= 0.5, NS, d = 0.22  TSI Sexual Behavior Problems  Mean (SD)  G1 Pre-tx: 9.2 (7.0)  G1 Post-tx: 7.0 (7.4)  G2 Pre-tx: 7.8 (7.4)  G2 Post-tx: 6.6 (7.1)  Treatment X Time Interaction at post-tx, F= 1.1, NS, d = 0.31  TSI Impaired Self-Reference  Mean (SD)  G1 Pre-tx: 14.8 (5.6)  G1 Post-tx: 11.4 (5.6)  G2 Pre-tx: 12.7 (6.2)  G2 Post-tx: 11.4 (5.3)  Treatment X Time Interaction at post-tx, F= 2.3, NS, d = 0.39  TSI Tension Reduction Behaviors  Mean (SD)  G1 Pre-tx: 9.3 (5.7)  G1 Post-tx: 7.3 (5.1)  G2 Pre-tx: 7.5 (5.3)  G2 Post-tx: 6.6 (5.3)  Treatment X Time Interaction at post-tx, F= 2.0, NS, d = 0.42 |  |  |  |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Friedman et al., 2007[70](#_ENREF_70) | G1: Sertraline  25 to 200 mg/day  G2: Placebo | HAM-A  Change at Endpoint (SE)  G1: -4.1 (1.0) G2: -6.1 (1.1)  Between Group Differences, NS  HAM-D  Change at Endpoint (SE)  G1: -2.7 (1.1)  G2: -4.2 (1.1)  Between Group Differences, NS | NR | NR | NR |
| Galovski et al., 2012[6](#_ENREF_6) | G1: Modified CBT. Modifications include potential addition of stressor sessions and variable length of treatment.  G2: Delayed treatment symptom monitoring | BDI-II  LSM (SE)  G1 Pre-tx: 30.06 (1.53) G1 Post-tx: 9.67 (2.06)  Difference: -20.2  G2 Pre: 32.50 (1.65) G2 Post: 25.51 (2.13)  Difference: -7.0  (Hedge's g = .92)  G1 vs. G2: -13.2, p < .001 | QOLI  LSM (SE) G1 Pre-tx LSM=1.18 (4.65) G1 Post-tx: 21.87 (5.69)  Point Improvement: 20.7, p  G2 Pre-tx: -.17 (4.81) G2 Post-tx: 3.05 (5.89)  Point Improvement: 3.2  (Hedge's g = .47)  G1 vs. G2: -17.4, p <0.025 | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Galovski et al., 2012[6](#_ENREF_6)  (continued) |  |  | SF-36 social functioning  G1 Pre-tx: 42.87 (4.06) G1 Post-tx: 73.87 (4.56) G2 Pre-tx: 37.45 (4.29) G2 Post-tx: 39.88 (4.69) (Hedge's g = .95)  G1 vs. G2: p < .001  SF-36 emotional well-being  G1 Pre-tx: 41.29 (2.77) G1 Post-tx: 66.51 (3.62) G2 Pre-tx: 40.89 (2.91) G2 Post-tx: 42.43 (3.83)  (Hedge's g = 1.04)  G1 vs. G2: p < .001  SF-36 general health  G1 Pre-tx: 50.43 (3.38) G1 Post-tx: 64.63 (3.48) G2 Pre-tx: 50.35 (3.56) G2 Post-tx: 50.53 (3.66)  (Hedge's g = .81) G1 vs. G2: p <.001 |  |  |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Gamito et al., 2010[141](#_ENREF_141) | G1: Virtual reality exposure therapy "VRET"  G2: CBT, exposure-based therapy (Imaginal exposure)  G3: WL | BDI  Mean (SD) G1 Pre-tx: 24.25 (9.46)  G1 Post-tx.: 14.25 (7.67) p=0.003  SCL-90-R (Psychopathology)  Depression  G1 Change, p=0.011  Somatization  G1 Change, p<0.01  Anxiety  G1 Change, p<0.05 | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Gersons et al., 2000[51](#_ENREF_51) | G1: Eclectic psychotherapy (Brief Eclectic Psychotherapy)  G2: WL | Symptom Checklist-90-Phobic Anxiety Subscale Mean (SD) G1 Pre-tx: 21.1 (7.3) G1 Post-tx: 13.4 (5.6) G1 3 mth FU: 13.8 (4.6)   G2 Pre-tx: 22.1 (11.0) G2 Post-tx:17.8 (7.4) G2 3 mth FU: 21.1 (7.6)   Post-tx G1 vs. G2, p<0.01 3-mth FU G1 vs. G2, p<0.05  Symptom Checklist-90-Anxiety Subscale  Mean (SD) G1 Pre-tx: 10.1 (3.1) G1 Post-tx: 7.7 (1.6) G1 3 mth FU: 7.6 (0.9)  G2 Pre-tx: 14.4 (4.7)  G2 Post-tx: 9.8 (3.7)  G2 3 mth FU: 9.8 (3.7)  Post-tx G1 vs. G2, p<0.01  3 mth FU G1 vs. G2, p<0.05  Symptom Checklist-90-Depression Subscale  Mean (SD)  G1 Pre-tx: 35.1 (14.6)  G1 Post-tx: 21.0 (7.4)  G1 3 mth FU: 21.6 (8.5) | NR | NR | Proportions by Treatment (%, p values)  Resumption of Polic work Pre-tx G1: 18% G2: 25% NS Post-tx G1: 77%  G2: 70% NS 3-month Followup G1: 86% G2: 60% p<0.05 |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Gersons et al., 2000[51](#_ENREF_51)  (continued) |  | G2 Pre-tx: 34.9 (13.0)  G2 Post-tx: 28.5 (9.6)  G2 3 mth FU: 30.5 (10.5)  Post-tx G1 vs. G2, p<0.01  3 mth FU G1 vs. G2, p<0.05 |  |  |  |
| Haller et al., 2016[145](#_ENREF_145) | G1: Group ICBT for depression and SUD plus CPT-M (trauma-focused CPT modified to include substance use prevention) (individual)  G2: Group ICBT for depression and SUD plus ICBT for depression and SUD (individual) | PDA  Mean (SD)  G1 Pre-tx: 0.84 (0.26)  G1 Post-tx: 0.81(0.28)  G1 Post-tx (1 year followup): 0.73 (0.32)  G2 Pre-tx: 0.81 (0.30)  G2 Post-tx: 0.79(0.29)  G1 Post-tx (1 year followup): 0.72 (0.40) | NR | NR | NR |
| Hamner et al., 2003[83](#_ENREF_83) | G1: Risperidone  1 to 6 mg/day  G2: Placebo | NR | NR | NR | NR |

| Author, Year | Intervention Groups | | Comorbid Medical Condition | QOL | Disability/Functional Impairment | | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Harned et al., 2014[144](#_ENREF_144) | G1: DBT plus DBT PE  G2: DBT | HRSD  Mean (SD)  G1 Pre-tx: 22.9 (5.7)  G1 Post-tx: 11.8 (8.0)  G1 3 month followup: 12.5 (8.2)  G2 Pre-tx: 25.6 (6.2)  G2 Post-tx: 15.5 (6.5)  G2 3 month followup: 16.8 (3.4)  Between Group Effect size, Post: 0.5, followup: 0.6  Treatment X time Interaction, F = 0.0 (1, 28), NS  HRSA  Mean (SD)  G1 Pre-tx: 25.8 (9.0)  G1 Post-tx: 14.2 (10.8)  G1 3 month followup: 15.0 (10.6)  G2 Pre-tx: 27.6 (10.9)  G2 Post-tx: 17.8 (8.6)  G2 3 month followup: 16.3 (7.0)  Between Group Effect size, Post: 0.3, followup: 0.1  Treatment X time Interaction, F = 0.6 (1, 22), NS | | NR | NR | NR | |

| Author, Year | Intervention Groups | | Comorbid Medical Condition | QOL | Disability/Functional Impairment | | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Harned et al., 2014[144](#_ENREF_144)  (continued) |  | GIS  Mean (SD)  G1 Pre-tx: 2.6 (0.6)  G1 Post-tx: 1.1 (0.7)  G1 3 month followup: 1.4 (0.9)  G2 Pre-tx: 2.2 (0.7)  G2 Post-tx: 1.2 (0.5)  G2 3 month followup: 1.7 (0.8)  Between Group Effect size, Post: 0.2, Followup: 0.2  Treatment X time Interaction, F = 0.6 (1, 16), NS | |  |  |  | |
| Hien et al., 2004[57](#_ENREF_57) | G1: Seeking Safety  G2: Relapse prevention condition  (only substance abuse)  G3: UC (Non-randomized Standard community Care) | NR | | NR | NR | NR | |
| Hien et al., 2009[157](#_ENREF_157)  Hien et al., 2012[158](#_ENREF_158) | G1: Seeking Safety  G2: Psychoeducation | NR | | NR | NR | NR | |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Hinton et al., 2005[34](#_ENREF_34) | G1: CBT-mixed  (Information on PTSD and Panic Disorder, relaxation techniques, culturally appropriate visualization, cognitive restructuring, exposure to anxiety-related sensations and trauma related memories, emotional-processing protocol, and cognitive flexibility)  G2: WL | Anxiety Sensitivity Index (ASI) Mean (SD) G1 Pre-tx: 3.08 (0.61) G1 2nd Assessment: 1.65 (0.45)  G1 3rd Assessment: 1.86 (1.98)  G1 FU Assessment: 1.98 (0.40)  G2 Pre-tx: 3.27 (0.53) G2 2nd Assessment: 3.19 (0.36)  G2 3rd Assessment 1.84 (0.42)  G2 FU Assessment: 1.91 (0.49)  Group Diffferences at 2nd Assessment, p<0.001  Group Differences at 1st, 3rd, & 4th assessments, NS  Average of the Symptom Checklist-90-R's Anxiety and Depression subscale (SCL) Mean (SD) G1 Pre-tx: 2.92 (0.61) G1 2nd Assessment: 1.72 (0.43)  G1 3rd Assessment: 1.77 (0.30)  G1 FU Assessment: 2.02 (0.78) | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Hinton et al., 2005[34](#_ENREF_34)  (continued) |  | G2 Pre-tx: 3.02 (0.51) G2 2nd Assessment: 2.94 (0.45)  G2 3rd Assessment: 2.03 (0.41)  G2 FU Assessment: 1.96 (0.89)  Group Diffferences at 2nd Assessment, p<0.001  Group Differences at 1st, 3rd, & 4th assessments, NS |  |  |  |
| Hinton et al., 2009[151](#_ENREF_151) | G1: CBT-Mixed  (Information on PTSD and Panic Disorder, muscle relaxation, guided imagery, mindfulness training, yoga-like stretching, cognitive restructuring, various exercises to teach emotional distancing and switching, and interoceptive exposure)  G2: WL | NR | NR | NR | NR |

| Author, Year | Intervention Groups | | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- | --- |
| Hinton et al., 2011[152](#_ENREF_152) | | G1; CBT-mixed  Culturally Adapted CBT (coping skills, cognitive "modification", mentions exposure)  G2: Applied Muscle Relaxation | SCL Anxiety Scale  Mean (SD)  G1 Pre-tx: 2.5 (0.5)  G1 Post-tx: 1.5 (0.7)  G1 FU: 1.4 (0.6)  G2 Pre-tx: 2.6 (0.6)  G2 Post-tx: 2.2 (0.7)  G2 FU: 2.1 (0.8)  Post-tx  G1 vs. G2, p<0.05 (t-test)  FU  G1 vs. G2, p<0.05 (t-test) | NR | NR | NR | |
| Hogberg et al., 2007[48](#_ENREF_48) | G1; EMDR  G2: WL | | BAI  Mean (SD) Pre-tx G1 Pre-tx: 16.7 (10.0)  G1 Post-tx: 9.5 (14.0)  G2 Pre-tx: 13.1 (9.3)  G2 Post-tx: 11.4 (4.9)  Within group change  G1: p<0.05 G2: NS  Between group change, NS  HAM-A  Mean (SD) G1 Pre-tx: 16.0 (6.5)  G1 Post-tx: 9.8 (7.2)  G2 Pre-tx: 18.2 (6.6)  G2 Post-tx: 16.1 (5.1) |  | GAF  Mean (SD) G1 Pre-tx: 64.0 (3.6)  G1 Post-tx: 78.9 (12.5)  G2 Pre-tx: 64.9 (3.9)  G2 Post-tx: 66.8 (6.0)  Within group change G1: p<0.05 G2: NS  Between group change, p<0.05  SDI  Mean (SD) G1 Pre-tx: 4.5 (2.3)  G1 Post-tx: 4.2 (3.3)  G2 Pre-tx: 5.9 (4.5)  G2 Post-tx: 5.4 (3.4) | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Hogberg et al., 2007[48](#_ENREF_48)  (continued) |  | Within group change G1: p<0.05 G2: NS  Between group change, NS  HAM-D  Mean (SD) G1 Pre-tx: 29.5 (3.5)  G1 Post-tx: 26.8 (5.0)  G2 Pre-tx: 30.0 (3.4)  G2 Post-tx: 31.3 (4.5)  Within group change G1: NS  G2: NS  Between group change, p<0.05 |  | Within group change G1: NS G2: NS  Between group change, NS |  |
| Hollifield et al., 2007[32](#_ENREF_32) | G1: Acupuncture  G2: CBT-mixed  (Cognitive restructuring, behavior activation, and coping skills)  G3: WL | Depression (HSCL-25)  Mean (SD)  G1 Pre-tx: 2.50 (0.70)  G1 Post-tx: 1.89 (0.76)  G1 3 mth FU: 1.88 (0.75)  G2 Pre-tx: 2.63 (0.53)  G2 Post-tx: 2.00 (0.63)  G2 3 mth FU: 1.91 (0.69)  G3 Pre-tx: 2.61 (0.65)  G3 Post-tx: 2.53 (0.67)  G3 3 mth FU: 2.53 (0.67)  RMANOVA  G1 vs. G2, p=0.77  G1 vs. G3, p<0.01  G2 vs. G3, p<0.01 | NR | SDI  Mean (SD) G1 Pre-tx: 3.78 (0.83)  G1 Post-tx: 2.98 (1.26)  G1 3 mth FU: 2.79 (1.32)  G2 Pre-tx: 4.09 (0.81)  G2 Post-tx: 3.30 (1.22)  G2 3 mth FU: 3.00 (1.29)  G3 Pre-tx: 4.00 (1.02) G3 Post-tx: 3.96 (1.04)  G3 3 mth FU: 3.96 (1.04)   G2 vs. G3, p<0.01 | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Hollifield et al., 2007[32](#_ENREF_32)  (continued) |  | Anxiety (HSCL-25)  Mean (SD)  G1 Pre-tx: 2.45 (0.57)  G1 Post-tx: 1.67 (0.72)  G1 3mth FU: 1.66 (0.56)  G2 Pre-tx: 2.40 (0.42)  G2 Post-tx: 1.78 (0.54)  G2 3 mth FU: 1.81 (0.61)  G3 Pre-tx: 2.26 (0.67)  G3 Post-tx: 2.14 (0.61)  G3 3 mth FU: 2.14 (0.61)  RMANOVA  G1 vs. G2, p=0.30  G1 vs. G3, p<0.01  G2 vs. G3, p<0.01 |  | RMANOVA G1 vs. G2, p=0.83  G1 vs. G3, p<0.01 |  |
| Ivarsson et al., 2014[24](#_ENREF_24) | G1: Internet based CBT  G2: Delayed treatment attention control | BDI-II (ITT)  Mean (SD)  G1 Pre-tx: 26.61 (11.42)  G1 Post-tx: 16.11 (10.49)  G2 Pre-tx: 26.35 (10.88)  G2 Post-tx: 22.19 (10.50)  Treatment by time interaction = -6.1 (95% CI, -10.7 to -1.6), t (58) = 2.7, p=0.009, d = 0.55 (95% CI, 0.00 to 1.09), favoring treatment  BAI (ITT)  Mean (SD)  G1 Pre-tx: 23.03 (10.27)  G1 Post-tx: 13.57 (8.15)  G1 Followup 1 year: 11.95 (9.33) | QOLI (ITT)  Mean (SD)  G1 Pre-tx: 0.14 (1.71)  G1 Post-tx: 1.15 (1.60)  G2 Pre-tx: 0.59 (1.65)  G2 Post-tx: 0.62 (1.93)  Treatment by time interaction = 0.89 (95% CI, 0.26 to 1.51), t (55) = 2.9, P =0.006, d = 0.53 (95% CI, -0.02 to 1.06), favoring treatment | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Ivarsson et al., 2014[24](#_ENREF_24)  (continued) |  | G2 Pre-tx: 22.61 (10.51)  G2 Post-tx: 20.08 (10.26)  Treatment by time interaction = -6.2 (95% CI, -10.3 to -2.1), t (55) = 3.0, P =0.004, d = 0.60 (95% CI, 0.04 to 1.13), favoring treatment |  |  |  |
| Johnson et al., 2011[29](#_ENREF_29) | G1: CBT-mixed  (Psychoeducation and CBT restructuring)  G2: UC | BDI  Mean (SD)  G1 Pre-tx: 24.17 (9.10)  G1 Post-tx: 10.68 (8.80)  G1 3 mth FU: 11.61 (10.69)  G1 6 mth FU: 8.16 (8.62)  G2 Pre-tx: 21.89 (11.54)  G2 Post-tx: 18.53 (12.12)  G2 3 mth FU: 15.73 (10.90)  G2 6 mth FU: 12.85 (11.87)  Time effect, p<0.0001  Treatment effect, p<0.01 |  | NR | NR |
| Kearney et al., 2013[159](#_ENREF_159) | G1: MBSR+TAU G2: TAU (VHA health system) | PHQ-9  Mean (SD) G1 Pre-tx: 15.92 (6)  G1 Post-tx: 12 (6)  G1 4 month followup: 12.39 (6)  G2 Pre-tx: 16.55 (5) G2 Post-tx: 15.45 (5) G2 4 Month: 15.61 (6)  Post-tx, Between group: d = -.62 (95%, CI, -1.24 to 0) 4 months, between group: d = -0.55 (95% CI, -1.18 to .08) | SF-8-MCS  Mean (SD) G1 Pre-tx: 30.87 (9)  G1 Post-tx: 38.27 (10)  G1 4 month followup: 37.46 (10)  G2 Pre-tx: 30.41 (8) G2 Post-tx: 31.4 (10) G2 4 Month: 62.17 (7)  Post-tx, Between group: d = 0.69 (95% CI, 0.07 to 1.32) 4 months, Between group = d = .57 (95% CI, -.06 to 1.2) |  | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Kearney et al., 2013[159](#_ENREF_159)  (continued) |  | BADS  Mean (SD) G1 Pre-tx: 65.38 (20)  Posttx Mindfulness: 75.33 (26)  4 month Mindfulness: 76.39 (25)  Pretx TAU: 65.71 (21) Posttx TAU: 64.21 (15) 4 Month TAU: 65.68 (19)  Post-tx, Between group: d = 0.52 (95% CI, -.11 to 1.15) 4 months, Between group: d = 0.47 (95% CI, -0.15 to 1.09) | Clinically meaningful change (>=10 points) at PostTx: Mindfulness: 12 (57.1%) TAU: 5 (25%) Clinically meaningful change (>=10 points) at 4months: Mindfulness: 8 (36.4%) TAU: 1 (25.6%)  SF-8-PCS  G1 Pre-tx: 43.43 (10)  G2 Post-tx: 41.42 (10)  G1 4 month followup: 43.53 (10)  G2 Pre-tx: 32.02 (10)  G2 Post-tx: 37.29 (11) G2 4 Month followup: 36.60 (9)  Post-tx, Between group: d = 0.39 (95% CI, -0.22 to 1)  4 months, Between group: d = 0.73 (95% CI, 0.09 to 1.31 |  |  |
| Krakow et al., 2001[52](#_ENREF_52) | G1: IRT  G2: WL | NR | SF-36: no significant changes for either group (results not provided) | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Krystal et al., 2011 [85](#_ENREF_85) | G1; Risperidone  1 to 4 mg/day  G2: Placebo | HAMA  Mean Difference (95% CI) 1.16 (-0.18 to 2.51) p=0.9  MADRS  Mean Difference (95% CI)  1.19  (-.029 to 2.68) p=0.09  PANNSS  Mean Difference (95% CI) -0.21 (-2.37 to 1.96)  p=0.85 | BLSI  Mean Difference (95% CI)  -0.32 (-4.04 to 3.40) p=0.87  SF-36V PCS  Mean Difference (95% CI)  -1.13 (-2.58 to 0.32) p=0.13  SF-36V MCS  Mean Difference (95% CI)  -0.26 (-2.13 to 1.61) p=0.79 | NR | NR |
| Kubany et al., 2003[35](#_ENREF_35) | G1: CBT, cognitive restructuring  G2: WL | BDI G1 Mean Change from Baseline (95% CI): 70.8 p<.05 G2 Mean Change from Baseline (95% CI): 67.5 (pretherapy 1); 64.5 (pretherapy 2) p<.05 | NR | NR | NR |
| Kubany et al., 2004[28](#_ENREF_28) | G1: CBT-Mixed (Cognitive Trauma Therapy-Battered Women)  G2: WL | BDI (ITT Sample)  Mean (SD)  G1 Pre-tx: 26.9 (10.1)  G1 Post-tx: 12.0 (14.2)  G2 Pre-tx: 27.4 (11.0)  G2 Post-tx: 28.7 (10.5)  Between group significance, NR | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Langkaas et al., 2017[142](#_ENREF_142) | G1: PE  G2: IRT | BDI-II  Mean (SD)  G1 Pre-tx: 25.6 (7.41)  G1 Post-tx: 13.0 (10.90)  G1 3 mth FU: 16.8 (9.68)  G2 Pre-tx: 23.6 (7.49)  G2 Post-tx: 16.4 (11.31)  G2 12 mth FU: 18.0 (12.10)  Treatment X Time Interaction, NS  SCL-90-R GSI  Mean (SD)  G1 Pre-tx: 1.94 (0.50)  G1 Post-tx: 0.99 (0.77)  G1 3 mth FU: 1.21 (0.72)  G2 Pre-tx: 1.77 (0.52)  G2 Post-tx: 1.18 (0.85)  G2 12 mth FU: 1.33 (0.81)  Treatment X Time Interaction, NS | QOL-Psychological  Mean (SD)  G1 Pre-tx: 2.13 (0.52)  G1 Post-tx: 3.20 (0.78)  G1 3 mth FU: 2.97 (0.77)  G2 Pre-tx: 2.34 (0.64)  G2 Post-tx: 2.91 (0.89)  G2 12 mth FU: 2.76 (0.98)  Treatment X Time Interaction, p = 0.05  QOL-Social  Mean (SD)  G1 Pre-tx: 2.71 (0.72)  G1 Post-tx: 3.28 (0.76)  G1 3 mth FU: 3.15 (0.81)  G2 Pre-tx: 2.82 (0.73)  G2 Post-tx: 3.25 (0.75)  G2 12 mth FU: 3.05 (0.83)  Treatment X Time Interaction, NS | NR | NR |
| Li et al., 2017[172](#_ENREF_172) | G1; Sertraline 135 mg  G2: Placebo | NR | NR | NR | NR |

| Author, Year | | Intervention Groups | | Comorbid Medical Condition | | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Lindauer et al., 2005[50](#_ENREF_50) | G1: Eclectic psychotherapy  Brief Eclectic Psychotherapy  G2: WL | | HADS-Depressive Subscore Mean (SD) G1 Pre-tx: 11.8 (4.3) G1 Post-tx: 8.0 (6.7)  G2 Pre-tx: 9.0 (3.5) G2 Post-tx: 9.1 (5.7)  G1 vs. G2, p>0.05   HADS-Anxiety Subscore Mean (SD) G1 Pre-tx: 13.1 (3.2) G1 Post-tx: 8.1 (4.8)  G2 Pre-tx: 11.3 (3.3) G2 Post-tx: 12.0 (4.7)  G1 vs. G2, p<0.05 | | NR | | NR | Patients on Sick Leave (%)  G1 Pre-tx: 66.7% G1 Post-tx: 33.3%  G2 Pre-tx: 50% G2 Post-tx: 50%  G1 vs. G2, NS |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Litz et al., 2007[33](#_ENREF_33) | G1: CBT-mixed  (Stress management skills, in vivo exposure, and relapse prevention)  G2: Internet-delivered supportive counseling | BAI  G1 Pre-tx: 18.70 (10.60)  G1 Post-tx: 8.43 (5.93)  G1 3mth FU: 6.11 (5.69)  G1 6 mth FU: 6.38 (5.21)  G2 Pre-tx: 20.92 (15.00)  G2 Post-tx: 12.59 (13.45)  G2 3 mth FU: 9.92 (8.19)  G2 6 mth FU: 14.43 (9.96)  ITT Analysis  Post-tx  Time effect, p<0.001  Completer Analysis  3 mth FU  G1 vs. G2, NS  6 mth FU  G1 vs. G2, p =0.06  BDI  G1 Pre-tx: 18.87 (9.52)  G1 Post-tx: 12.14 (9.56)  G1 3 mth FU: 12.51 (6.53)  G1 6 mth FU: 8.50 (7.54)  G2 Pre-tx: 24.43 (12.08)  G2 Post-tx: 17.47 (11.19)  G2 3 mth FU: 13.23 (9.08)  G2 6 mth FU: 16.84 (8.66) | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Litz et al., 2007[33](#_ENREF_33)  (continued) |  | ITT Analysis  Post-tx  Time effect, p<0.001  Completer Analysis 3 mth FU G1 vs. G2, NS 6 mth FU G1 vs. G2, p<0.05 |  |  |  |
| Maguen et al., 2017[25](#_ENREF_25) | G1: CBT, Impact of Killing (IOK)  G2: WL | BSI  Mean (SD)  G1 Pre-tx: 59.6 (39.8)  G1 Post-tx: 41.9 (24.9)  Mean change: -17.73 (-32.87 to 2.6), t-test p = 0.0248  G2 Pre-tx: 58.7 (30.9)  G2 Post-tx: 63.2 (34.6)  Mean change: 4.53 (-6.65 to -15.71), t-test p = 0.3991  Between-group difference: -21.92 (-37.27 to -6.57) t-test p=, 0.16 | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Markowitz et al., 2015[132](#_ENREF_132)  Markowitz et al., 2016[261](#_ENREF_261) | G1: PE  G2: IPT  G3: RT | HAM-D  Mean (SD)  G1 Pre-tx: 20.2 (6.7)  G1 Post-tx: 12.3 (8.8)  Change at Post-tx: 7.3, Effect size: 1.07  G2 Pre-tx: 18.3 (6.5)  G2 Post-tx: 13.8 (8.8)  Change at Post-tx: 4.2, Effect size: 0.62  G3 Pre-tx: 21.0 (7.1)  G3 Post-tx: 14.8 (9.1)  Change at Post-tx: 7.0, Effect size: 1.03  Treatment X Time Interaction at post-tx, X2= 0.128, p = 0.880  G1 vs. G3 Difference: -4.42, p = 0.034, Effect Size: -0.65  G2 vs. G3 Difference: -0.98, p = 0.642, Effect Size: -0.14  G2 vs. G1 Difference: 3.44, p = 0.065, Effect Size: 0.51 | Quality of Life Enjoyment and Satisfaction  Mean (SD)  G1 Pre-tx: 43.5 (14.7)  G1 Post-tx: 63.5 (19.2)  Change at Post-tx: -17.9, Effect size: -1.33  G2 Pre-tx: 43.9 (15.0)  G2 Post-tx: 54.6 (18.2)  Change at Post-tx: -11.3, Effect size: -0.84  G3 Pre-tx: 43.1 (8.7)  G3 Post-tx: 46.1 (19.2)  Change at Post-tx: -0.8, Effect size: -0.06  Treatment X Time Interaction at post-tx, X2= 3.561, p = 0.037  G1 vs. G3 Difference: 17.83, p < 0.001, Effect Size: 1.33 | Social Adjustment Scale  Mean (SD)  G1 Pre-tx: 2.7 (0.6)  G1 Post-tx: 2.1 (0.5)  Change at Post-tx: 0.4, Effect size: 0.81  G2 Pre-tx: 2.7 (0.6)  G2 Post-tx: 2.2 (0.5)  Change at Post-tx: 0.5, Effect size: 0.93  G3 Pre-tx: 2.8 (0.4)  G3 Post-tx: 2.7 (0.6)  Change at Post-tx: 0.1, Effect size: 0.16  Treatment X Time Interaction at post-tx, X2= 3.875, p = 0.022  G1 vs. G3 Difference: -0.57, p < 0.001, Effect Size: -1.05  G2 vs. G3 Difference: -0.46, p = 0.001, Effect Size: -0.83  G2 vs. G1 Difference: 0.12, p = 0.409, Effect Size: 0.21 | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Markowitz et al., 2015[132](#_ENREF_132)  Markowitz et al., 2016[261](#_ENREF_261)  (continued) |  |  | G2 vs. G3 Difference: -10.13, p = 0.017, Effect Size: 0.75  G2 vs. G1 Difference: -7.69, p = 0.061, Effect Size: -0.57 | Inventory of Interpersonal Problems  Mean (SD)  G1 Pre-tx: 1.7 (0.6)  G1 Post-tx: 1.1 (0.6)  Change at Post-tx: 0.7, Effect size: 1.26  G2 Pre-tx: 1.6 (0.6)  G2 Post-tx: 1.0 (0.7)  Change at Post-tx: 0.5, Effect size: 0.95  G3 Pre-tx: 1.5 (0.4)  G3 Post-tx: 1.5 (0.6)  Change at Post-tx: -0.1, Effect size: -0.19  Treatment X Time Interaction at post-tx, X2= 3.875, p = 0.022  G1 vs. G3 Difference: -0.57, p < 0.001, Effect Size: -1.05  G2 vs. G3 Difference: -0.46, p = 0.001, Effect Size: -0.83  G2 vs. G1 Difference: 0.12, p = 0.409, Effect Size: 0.21 |  |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Marks et al., 1998[122](#_ENREF_122)  Lovell et al., 2001[123](#_ENREF_123) | G1: CBT, exposure-based therapy(PE)  G2: CBT, cognitive restructuring  G3: CBT-mixed  Exposure (Combined with Cognitive Restructuring)  G4: Relaxation | BDI (11 weeks) Mean Change Score (95% CI) G1: 13 (8 to 18) G2: 17 (11 to 22) G3: 18 (13 to 23) G4: 7 (3 to 11)  Additional results presented in graphs  BDI  Mean change in G1 + G2 + G3 vs. G4  Post, p=0.004  1 mth FU, p=0.08 | NR | Work/Social Adjustment (Self Report) (Completer data) Mean (SD) G1 Pre-tx: 21.5 (8.9)  G1 Post-tx:11.8 (12.3)  G1 1 mth FU: 9.5 (12.1) G1 3 mth FU: 5.2 (8.3) G1 6 mth FU: 4.1 (7.8)  G2 Pre-tx: 26.9 (8.8)  G2 Post-tx:14.3 (10.0)  G2 1 mth FU:13.9 (10.9) G2 3 mth FU: 14.7 (12.1) G2 6 mth FU: 13.4 (11.7)  G3 Pre-tx: 29.4 (7.9)  G3 Post-tx:13.2 (12.1)  G3 1 mth FU: 13.2 (12.2) G3 3 mth FU: 10.3 (9.3) G3 6 mth FU: 4.5 (6.9)  G4 Pre-tx: 22.1 (9.5)  G4 Post-tx:17.5 (11.6)  G4 1 mth FU: 15.0 (11.3) G4 3 mth FU: 14.9 (12.3)  Additional results presented in graphs  Work/Social Adjustment Mean change in G1 + G2 + G3 vs. G4  Post, p=0.002  1 mth FU, p=0.006  3 mth FU, p=0.005 | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Marshall et al., 2001[64](#_ENREF_64) | G1: Paroxetine  20 mg/day  G2: Paroxetine  40 mg/day  G3: Placebo | MADRS Adjusted Mean Differences (95% CI)  G1 vs. G3 -5.6 (-8.0 to -3.3)  p<0.001  G2 vs. G3 -5.1 (-7.4 to -2.8)  p<0.001 | NR | SDS Adjusted Mean Differences (95% CI) G1 vs. G3 -2.4 (-4.1 to -0.8)  p<0.005  G2 vs. G3 -2.0 (-3.7 to -0.3)  p<0.001 | NR |
| Martenyi et al., 2002[61](#_ENREF_61)  Martenyi et al., 2006[173](#_ENREF_173) | G1: Fluoxetine  20 to 80 mg/day  G2: Placebo | MADRS  Changes from Pre-tx to Post-tx Least Square Means (SE), p-value G1: -6.5 (0.45) G2: -3.5 (0.75) p<0.001  HAM-A  Changes from Pre-tx to Post-tx Least Square Means (SE), p-value G1: -8.7 (0.48) G2: -5.7 (0.79) p=0.001  Hopkins 90-Item Symptom Checklist-Revised (SCL-90-R) Changes from Pre-tx to Post-tx Least Square Means (SE), p-value G1: -51.8 (4.40) G2: -36.4 (7.20) p=0.058 | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Martenyi et al., 2007[62](#_ENREF_62) | G1: Fluoxetine  20 mg/day  G2: Fluoxetine  40 mg/day  G3: Placebo | MADRS  Mean change from baseline (SE) (Completer analysis)  G1: -5.05 (0.82)  G2: -5.04 (0.84)  G3: -3.45 (1.14)  p =0 .463  HAMA  Mean change from baseline (SE) (Completer analysis)  G1: -9.12 (0.61)  G2: -9.16 (0.62)  G3: -7.67 (0.84)  p=.296 |  |  |  |
| Maxwell et al., 2016[124](#_ENREF_124) | G1: MEST  G2: CPT | BDI-II  Mean (SD)  G1 Pre-tx:26.13 (11.31)  G1 Post-tx:20.25 (16.03)  G1 3 mth FU: 18.13 (13.27)  G2 Pre-tx:23.63 (16.27)  G2 Post-tx:14.75 (10.99)  G2 3 mth FU: 11.38 (11.08)  Cohen’s d = .40 | NR | GAF  Mean (SD)  G1 Post-tx:67.25 (16.60)  G2 Post-tx:69.44 (10.04)  Cohen’s d = -0.16 | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| McDonagh et al., 2005[39](#_ENREF_39) | G1: CBT-mixed (  Exposure and cognitive restructuring therapy)  G2: PCT  G3: WL | BDI  Mean (SD)  G1 Pre-tx: 18.9 (9.6)  G1 Post-tx: 12.9 (12.5)  G2 Pre-tx: 17.0 (7.7)  G2 Post-tx: 10.8 (9.5)  G3 Pre-tx: 20.9 (7.8)  G3 Post-tx: 19.0 (11.3)  Group X Time, p>0.10  STAI  Mean (SD)  G1 Pre-tx: 53.5 (10.4)  G1 Post-tx: 46.2 (13.9)  G2 Pre-tx: 54.5 (9.2)  G2 Post-tx: 46.4 (12.2)  G3 Pre-tx: 54.6 (9.6)  G3 Post-tx: 51.5 (9.7)  Group X Time, p<0.10 | QOLI Mean (SD) G1 Pre-tx: 36.1 (15.9) G1 Post-tx: 39.5 (17.0)   G2 Pre-tx: 35.2 (15.3) G2 Post-tx: 39.0 (12.6)  G3 Pre-tx: 36.8 (13.2) G3 Post-tx: 37.2 (14.7)  Group X Time, p>0.10 | NR | NR |

| Author, Year | Intervention Groups | | Comorbid Medical Condition | QOL | Disability/Functional Impairment | | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- | --- | --- |
| McGovern et al., 2015[27](#_ENREF_27) | G1: ICBT plus SC, manual-guided therapy focused on PTSD and  substance use.  G2: IAC plus SC, (focused exclusively on  substance use and recovery) (arm not eligible)  G3: SC (intensive out-patient program services) | Positive toxicology, n (%)  G1 Pre-tx: 16 (21.9)  G1 Post-tx (6 month): 10(18.5)  G3 Pre-tx: 15 (20.8)  G3 Post-tx (6 month):19(38.8)  Difference between G1 and G3, p <0.05  Parameter Estimate and CIs for ANCOVA  G1 vs. G3, 1.13 (95% CI, 0.18 to 2.08)  Effect size  G1 vs. G2: -0.45  ASI-Drug, Mean (SD)  G1 Pre-tx: 0.13 (0.09)  G1 Post-tx (6 month): 0.08(0.08)  G3 Pre-tx: 0.15 (0.09)  G3 Post-tx (6 month):0.09(0.09)  Difference between G1 and G3, NS  Parameter Estimate and CIs for ANCOVAG1 vs. G3, -0.01 (95% CI, -0.04 to 0.02)  Effect size  G1 vs. G2: -0.13  ASI-alcohol, Mean (SD)  G1 Pre-tx: 0.21 (0.22)  G1 Post-tx (6 month): 0.15 (0.19) | | NR | NR | NR | |

| Author, Year | Intervention Groups | | Comorbid Medical Condition | QOL | Disability/Functional Impairment | | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Mills et al., 2012[20](#_ENREF_20) | G1: COPE, a modification of Concurrent Treatment of PTSD and Cocaine Dependence. (motivational enhancement, psychoeducation, in vivo exposure, imaginal exposure, and cognitive therapy)  G2: TAU | BDI-II  Mean (95% CI) G1 Pre-tx: 36.07 (33.17 to 38.97)  G1 Post-tx:  24.44 (19.29 to 29.59)  Mean difference Pre-tx to FU: -11.64 (-17.08 to -6.19), p < 0.001  G2 Pre-tx: 31.69 (28.08, 35.30)  G2 Post-tx: 24.78 (20.15, 29.41) Mean difference Pre-tx to Post-tx: -6.90 (-10.84, -2.97), p < 0.001  Between group difference Pre-tx to Post-tx: -4.73 (-11.76, 2.29), NS  Treatment X Time Interaction: X2 = 1.31, p = 0.26  STAI  Mean (95% CI) G1 Pre-tx: 54.69 (51.16, 58.22)  G1 Post-tx: 46.44 (42.09 to 50.79)  Mean difference Pre-tx to Post-tx: -8.25 (-13.64 to -2.86), p < 0.001  G2 Pre-tx: 50.42 (46.89 to 53.95) G2 Post-tx: 47.50 (43.15 to 51.85) Mean difference Pre-tx to Post-tx: -2.91 (-7.16 to 1.34), NS | | NR | NR | NR | |

| Author, Year | Intervention Groups | | Comorbid Medical Condition | QOL | Disability/Functional Impairment | | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Mills et al., 2012[20](#_ENREF_20) |  | Between group difference Pre-tx to post-tx: -5.34 (-12.47 to 1.80), NS  Treatment X Time Interaction: X2 = 2.69, p = 0.10  Number of Drug Classes Used  Mean (95% CI)  G1 Pre-tx: 3.71 (3.32 to 4.10)  G1 Post-tx: 2.13 (1.68 to 2.58)  Mean difference Pre-tx to Post-tx: 0.57 (0.46 to 0.72), p < 0.001  G2 Pre-tx: 3.81 (3.40 to 4.22)  G2 Post-tx: 2.28 (1.71 to 2.85)  Mean difference Pre-tx to post-tx: 0.60 (0.47 to 0.76), p<0.001  Between group difference Pre-tx to post-tx: 0.96(0.69, 1.34), NS  Treatment X Time Interaction: X2 = 0.10, p = 0.76  Number of Dependence Criteria Met  Mean (95% CI)  G1 Pre-tx: 5.33 (5.09 to 5.57)  G1 Post-tx: 2.27 (1.58 to 2.96)  Mean difference Pre-tx to Post-tx: 0.43 (0.31 to 0.58), p < 0.001 | |  |  |  | |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Mills et al., 2012[20](#_ENREF_20) |  | G2 Pre-tx: 5.58 (5.36 to 5.80)  G2 Post-tx: 2.98 (2.27 to 3.69)  Mean difference Pre-tx to post-tx: 0.52 (0.41 to 0.66), p>0.001  Between group difference Pre-tx to post-tx: 0.85 (0.60 to 1.21), NS  Treatment X Time Interaction: X2 = 0.00, p >0.99 |  |  |  |
| Monnelly et al., 2003[167](#_ENREF_167) | G1: Risperidone  0.5 to 2.0mg/day  G2: Placebo | NR | NR | NR | NR |
| Monson et al., 2006[1](#_ENREF_1) | G1:CBT, cognitive processing therapy  G2: WL | BDI  Mean (SE) G1 Pre-tx: 25.39 (1.8) G1 Post-tx: 17.42 (1.6) G1 1 mth FU: 18.75 (1.9)  G2 Pre-tx: 28.53 (1.6) G2 Post-tx: 27.06 (1.4) G2 1 mth FU: 23.92 (1.8)  Group X Time, NS  STAI Mean (SE) G1 Pre-tx: 54.38 (2.1) G1 Post-tx: 46.92 (2.1) G1 1 mth FU: 47.51 (2.4)  G2 Baseline: 55.62 (1.8) G2 Postassessment: 58.16 (2.0) G2 1-month followup: 56.98 (2.3)  Group X Time, p<0.01 | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Monson et al., 2012[22](#_ENREF_22) | G1: CBCT, manualized cognitive-behavioral conjoint therapy for PTSD delivered in a couple therapy format  G2: WL | Beck Depression  Mean (95% CI)  G1 Pre-tx: 24.36 (19.59 to 29.12)  G1 Post-tx: 12.16 (6.35 to 17.96)  Change: -12.20 (-19.10 to -5.31)  Effect size Hedge g: 1.16 (0.40 to 1.89)  G2 Pre-tx: 22.60 (17.88 to 27.32)  G2 Post-tx: 20.32 (14.79 to 25.85)  Change: -2.29 (-6.37 to -1.79)  Effect size Hedge g: 0.17 (-0.13 to 0.47)  Change Difference Mean Between Groups: -9.91 (-17.22 to -2.60)  Effect size Hedge g: 0.83 (0.10 to 1.54)  Treatment X Time Interaction, t (40, 7) = -2.87, p = 0.007  State-Trait Anxiety Scale  Mean (95% CI)  G1 Pre-tx: 49.25 (43.67 to 54.82)  G1 Post-tx: 38.65 (31.97 to 45.32)  Change: -10.60 (-19.04 to -2.16)  Effect size Hedge g: 0.84 (0.17 to 1.49)  G2 Pre-tx: 50.90 (45.47 to 56.33)  G2 Post-tx: 51.73 (45.47 to 57.99)  Change: 0.84 (-4.40 to 6.08)  Effect size Hedge g: -0.06 (-0.41 to 0.29)  Change Difference Mean Between Groups: -11.43 (-20.55 to -2.31)  Effect size Hedge g: 0.85 (0.13 to 1.57)  Treatment X Time Interaction, t (44) = -2.62, p = 0.01 | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Moradi et al., 2014[160](#_ENREF_160) | G1: MEmory Specificity Training (MEST)  G2: Control, no additional contact | BDI-II  Treatment X Time Interaction, NS | NR | NR | NR |
| Morath et al., 2014[55](#_ENREF_55) | G1: NET  G2: WL | HAM-D  Mean (SD)  G1 Pre-tx: 22.82 (11.73)  G1 Post-tx: 17.00 (9.81)  G1 1 year post-tx:17.63 (9.84)  G2 Pre-tx: 25.94 (6.55)  G2 Post-tx: 24.18 (9.21)  Treatment X Time Interaction at post-tx, F (1, 32) = 0.89, p = 0.35  SOMS  Mean (SD)  G1 Pre-tx: 25.12 (10.55)  G1 Post-tx: 19.18 (14.93)  G1 1 year post-tx:16.81 (10.00)  G2 Pre-tx: 23.00 (12.75)  G2 Post-tx: 26.31 (12.38)  Treatment X Time Interaction at post-tx, F (1, 32) = 6.19, p = 0.02 | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Mueser et al., 2008[7](#_ENREF_7) | G1: CBT-mixed  (CBT for PTSD)  G2: UC | BDI-II  Mean (SD) G1 Pre-tx: 31.48 (13.24) G1 Post-tx: 21.91 (11.52) G1 3 mth FU: 21.67 (13.32) G1 6 mth FU: 25.02 (12.85)  G2 Pre-tx: 31.76 (13.76) G2 Post-tx: 27.70 (14.75) G2 3 mth FU: 30.66 (15.26) G2 6 mth FU: 31.30 (13.50)  Group effect, p<0.001  BAI Mean (SD) G1 Pre-tx: 48.29 (13.04) G1 Post-tx: 42.59 (12.95) G1 3 mth FU: 41.10 (14.29) G1 6 mth FU: 43.58 (12.03)  G2 Pre-tx: 49.68 (13.26) G2 Post-tx: 45.81 (14.16) G2 3 mth FU: 48.04 (15.62) G2 6 mth FU: 47.84 (13.73)  Group effect, p =0.03 | SF-12 - Physical  Mean (SD) G1 Pre-tx: 39.81 (11.63) G1 Post-tx: 39.23 (11.26) G1 3 mth FU: 39.17 (13.61) G1 6 mth FU: 38.89 (13.44)  Group effect, p=.002  G2 Pre-tx: 40.74 (11.54) G2 Post-tx: 39.34 (12.98) G2 3 mth FU: 38.14 (11.59) G2 6 mth FU: 35.81 (10.72)  Group effect, p=0.002 | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Mueser et al., 2008[7](#_ENREF_7)  (continued) |  | Brief Psychiatric Rating Scale  Mean (SD)  G1 Pre-tx: 43.92 (7.69)  G1 Post-tx: 39.63 (10.00)  G1 3 mth FU: 40.57 (7.33)  G1 6 mth FU: 41.78 (6.81)  G2 Pre-tx: 43.77 (7.42)  G2 Post-tx: 42.25 (7.59)  G2 3 mth FU: 43.97 (10.37)  G2 6 mth FU: 46.60 (11.56)  Group effect, p =0.02 | SF-12-Mental  Mean (SD) G1 Pre-tx:: 29.35 (9.57) G1 Post-tx: 33.81 (11.02) G1 3 mth FU: 33.92 (11.03) G1 6 mth FU: 31.19 (9.12)  G2 Pre-tx: 29.37 (9.05) G2 Post-tx: 33.75 (10.93) G2 3 mth FU: 29.99 (11.44) G2 6 mth FU: 26.66 (10.01)  Group effect, p=0.13 |  |  |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Nacasch et al., 2011[15](#_ENREF_15) | G1: CBT, exposure-based therapy (PE)  G2: TAU | BDI  Mean (SD)  G1 Pre-tx: 26.0 (7.9)  G1 Post-tx: 13.2 (7.6)  G2 Pre-tx: 31.4 (8.8)  G2 Post-tx: 26.8 (10.7)  Post-tx  Treatment X Time, NS  G1 vs. G2, p=0.007  STAI - State  Mean (SD)  G1 Pre-tx: 59.5 (11.6)  G1 Post-tx: 44.3 (11.0)  G2 Pre-tx: 60.9 (13.3)  G2 Post-tx: 62.0 (12.3)  Post-tx  Treatment X Time, p=0.007  G1 vs. G2, p<0.001  STAI - Trait  Mean (SD)  G1 Pre-tx: 59.5 (8.3)  G1 Post-tx: 47.7 (12.6)  G2 Pre-tx: 61.0 (10.9)  G2 Post-tx: 61.7 (12.5)  Post-tx  Treatment X Time, p=0.016  G1 vs. G2, p=0.017 | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Neuner et al., 2004[161](#_ENREF_161) | G1: CBT, exposure-based therapy (NET)  G2: Supportive Counseling  G3: Psycho-education  About the nature and prevalence of PTSD | Self-Reporting Questionnaire 20 (SRQ-20) Mean (SD) G1 Pre-tx: 15.6 (2.9)  G1 Post-tx: 13.1 (5.1)  G1 4 mth FU: 11.9 (4.9) G1 1 year FU: 11.0 (5.1)  G2 Pre-tx: 16.5 (2.7)  G2 Post-tx: 14.3 (5.0)  G2 4 mth FU: 12.8 (3.9) G2 1 year FU: 12.4 (4.8)  G3 Pre-tx: 18.6 (2.0)  G3 Post-tx: 15.3 (3.2)  G3 4 mth FU: 15.1 (2.6) G3 1 year FU: 14.4 (4.1)  Group X Time, NS  G1 vs. G2, p<0.01  G1 vs. G3, NS | SF-12, Psychological health Scale Mean (SD) G1 Pre-tx: 0.27 (0.12)  G1 Post-tx: 0.36 (0.19)  G1 4 mth FU: 0.38 (0.12) G1 1 year FU: 0.44 (0.19)  G2 Pre-tx: 0.34 (0.11)  G2 Post-tx: 0.33 (0.21)  G2 4 mth FU: 0.33 (0.14) G2 1 year FU: 0.36 (0.14)  G3 Pre-tx: 0.23 (0.15)  G3 Post-tx: 0.33 (0.19)  G3 4 mth FU:0.37 (0.14)  G3 1 year FU: 0.35 (0.17)  Group X Time, NS  G1 vs. G2, NS  G1 vs. G3, NS |  | NR |
| Neuner et al., 2008[54](#_ENREF_54) | G1: CBT, exposure based (NET)  G2: Flexible Trauma Counseling  G3: No-treatment monitoring group | NR | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Neuner et al., 2010[53](#_ENREF_53) | G1: CBT, exposure based (NET)  G2: UC | Hopkins Symptom Checklist - 25 Depression Scale  Mean (SD) G1 Pre-tx: 3.0 (0.4) G1 Post-tx: 2.6 (0.6)  G2 Pre-tx: 3.0 (0.5) G2 Post-tx: 2.9 (0.5)  Group X Time, NS | NR | NR | NR |
| Nijdam et al., 2012[154](#_ENREF_154) | G1: Eclectic psychotherapy  G2: EMDR | HADS - Depression  Mean Estimated Differences @ first f/u:  3.58 (1.68 to 5.49)  p<0.001  Mean Estimated Differences @ 2nd  f/u: 1.47 (-0.44 to 3.39)  p= 0.13  HADS-Anxiety  Mean Estimated Differences @ 2nd f/u:  3.74 (2.03 to 5.46)  p<0.001  HADS-Anxiety  Mean Estimated Differences @ 2nd f/u:  0.80 (-0.93 to 2.50)  p=0.36  MDD in G1  % @ baseline: 67.1  % @ 1st f/u: 36.4  % @ 2nd f/u: 19 | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Nijdam et al., 2012[154](#_ENREF_154)  (continued) |  | MDD in G2  % @ baseline: 52.9  % @ 1st f/u: 13.7  % @ 2nd f/u: 14.6  MDD between group difference @ 1st f/u: p<0.05  MDD between group difference @ 2nd f/u: p=0.57  Anxiety in G1  % @ baseline: 20  % @ 1st f/u: 9.1  % @ 2nd f/u: 11.9  Anxiety in G2  % @ baseline: 11.4  % @ 1st f/u: 9.8  % @ 2nd f/u: 10.4  MDD between group difference @ 1st f/u: p=0.91  MDD between group difference @ 2nd f/u: p=0.82 |  |  |  |
| Panahi et al., 2011[71](#_ENREF_71) | G1: Sertraline  50 to 200 mg/day  G2: Placebo | NR | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Petrakis et al., 2011[185](#_ENREF_185) | G1: Paroxetine (40 mg/day)+ Naltrexone (50 mg/day)  Participants who could not tolerate the highest dose were brought to lower doses.  G2: Paroxetine (40 mg/day) +Placebo  Participants who could not tolerate the highest dose were brought to lower doses.  G3: Desipramine (200 mg/day) + Naltrexone (50 mg/day)  Participants who could not tolerate the highest dose were brought to lower doses.  G4: Desipramine (200 mg/day + Placebo  Participants who could not tolerate the highest dose were brought to lower doses. | HAM-D Mean(SE) G1 Pre-tx: 13.273 (1.112) G1 Post-tx:9.328 (1.256)  G2 Pre-tx: 10.950 (1.167) G2 Post-tx:8.238 (1.299)  G3 Pre-tx: 11.195 (1.132) G3 Post-tx: 8.563 (1.201)  G4 Pre-tx: 13.167 (1.065) G4 Post-tx: 8.943 (1.117)  Time effect, p<0.00  Group X Time, NS | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Polusny et al., 2015[136](#_ENREF_136) | G1: 8 weekly group sessions and a daylong retreat. 1st session was an orientation that included rational and psychoeducation. 7 sessions of mindfulness therapy and 1 6.5 hour retreat.  G2: Group Sessions | PHQ-9  Mean (95% CI) G1 Pre-tx: 15.5 (13.9 to 17.0)  G1 Post-tx: 13.6 (12.0 to 15.1)  G1 2 month followup: 13.3 (11.7 to 15.0)  G2 Pre-tx: 14.6 (13.1 to 16.2)  G2 Post-tx: 13.9 (12.3 to 15.4) G2 2 month followup: 13.8 (12.2 to 15.4)  Post-tx, Between group mean difference: 1.17 (-0.22 to 2.56), p = .1 2 month, Between group mean difference: 1.34 (-0.07 to 2.75, p=0.06  Clinically significant improvement:  Posttx Mindfulness - 15 (29.4%) Posttx PCT - 11 (19.4%) 2 month Mindfullness - 13 (27.7%) 2 month PCT - 13 (22.8%)  Mean difference at Posttx: 9.8%, p = .24 Mean difference at 2 months: 4.9%, p= .57 | WHOQOL-BREF  Mean (95% CI) G1 Pre-tx: 75.6 (71.6 to 79.7)  G1 Post-tx: 80.7 (76.5 to 84.8)  G1 2 month followup: 80.2 (75.9 to 84.4)  G2 Pre-tx: 76.4 (72.3 to 80.4) G2 Post-tx: 78.5 (74.4 to 82.6) G2 2 month followup: 75.8 (71.7 to 79.9)  Post-tx, Between group mean difference: 3.1, p = 0.08 2 month, Between group mean difference: 5.22, p=0.004 | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Raskind et al., 2003[74](#_ENREF_74) | G1: Prazosin  2 to 10 mg/day  G2: Placebo | NR | NR | NR | NR |
| Raskind et al., 2007[75](#_ENREF_75) | G1: Prazosin  2 to 15 mg at bedtime  G2: Placebo | HAM-D Mean (SD) G1 Pre-tx: 18.3 (8.8) G1 Post-tx: 12.7 (7.7)  G2 Pre-tx: 15.3 (7.8) G2 Post-tx: 14.7 (7.1) G1 vs. G2 Change, p=0.08 | NR | NR | NR |
| Raskind et al., 2013[76](#_ENREF_76) | G1: Prazosin 1 to 5 mg/day morning dose, 1 to 20mg/day bedtime dose  G2: Placebo | HAM-D  Adjusted Means (95% CI)  G1 Pre-tx: 11.9 (9.5 to 14.3)  G1 Post-tx: 10.0 (7.5 to 12.5)  G2 Pre-tx: 14.7 (12.4 to 17.0)  G2 Post-tx: 14.7 (12.3 to 17.1)  Between Group Difference in Change from Baseline: 2.0 (-0.8 to 4.8), t = 1.39, p = 0.17 | NR | NR | NR |
| Reger et al., 2016[18](#_ENREF_18) | G1: VRE  G2: PE  G3: WL (minimum attention) | BDI-II  Mean (SD)  G1 Pre-tx: 27.87 (9.19)  G1 Post-tx: 18.50 (12.70)  G1 12 week: 20.04 (12.41)  G1 26 week: 18.59 (11.03)  G2 Pre-tx: 28.02 (11.18)  G2 Post-tx: 17.06 (16.18)  G2 12 week: 13.70 (13.52)  G2 26 week: 14.42 (13.38)  G3 Pre-tx: 27.67(9.99)  G3 Post-tx: 25.63 (12.87) | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Reger et al., 2016[18](#_ENREF_18)  (continued) |  | G1 vs. G3 Post-tx Differences: -7.87 (95% CI, -11.89 to -3.85), p <0.001, ES = -0.78 (95% CI, -1.18 to -0.38)  G2 vs. G3 Post-tx Differences: -9.09 (95% CI, -12.97 to -5.20), p <0.001, ES = -0.90 (95% CI, -1.29 to -0.52)  G1 vs. G2 Post-tx Differences: 1.22 (95% CI, -3.01 to 5.44), p = 0.714, ES = 0.12 (95% CI, -0.30 to 0.54)  G1 vs. G2 12 week Differences: 4.46 (95% CI, -0.05 to 8.98), p = 0.974, ES = 0.44 (95% CI, -0.01 to 0.89)  G1 vs. G2 26 week Differences: 4.63 (95% CI, -0.32 to 9.58), p = 0.967, ES = 0.46 (95% CI, -0.03 to 0.95  BAI  Mean (SD)  G1 Pre-tx: 24.57 (11.19)  G1 Post-tx: 17.17 (12.80)  G1 12 week: 19.28 (14.92)  G1 26 week: 15.24 (12.19)  G2 Pre-tx: 22.11 (9.34)  G2 Post-tx: 13.28 (12.11)  G2 12 week: 11.44 (11.79)  G2 26 week: 9.83 (10.02) |  |  |  |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Reger et al., 2016[18](#_ENREF_18)  (continued) |  | G3 Pre-tx: 23.81 (11.09)  G3 Post-tx: 18.83 (11.93)  G1 vs. G3 Post-tx Differences: -5.31 (95% CI, -9.37 to -1.25), p = 0.005, ES = -0.50 (95% CI, -0.89 to -0.12)  G2 vs. G3 Post-tx Differences: -5.46 (95% CI, -9.40 to -1.52), p = 0.003, ES = -0.52 (95% CI, -0.89 to -0.14)  G1 vs. G2 Post-tx Differences: 0.15 (95% CI, -4.14 to 4.44), p = 0.527, ES = 0.01 (95% CI, -0.39 to 0.42)  G1 vs. G2 12 week Differences: 3.51 (95% CI, -1.08 to 8.09), p = 0.933, ES = 0.33 (95% CI, -0.10 to 0.77)  G1 vs. G2 26 week Differences: 3.01 (95% CI, -2.02 to 8.03), p = 0.880, ES = 0.28 (95% CI, -0.19 to 0.76 |  |  |  |
| Reich et al., 2004[84](#_ENREF_84) | G1: Risperidone  0.5 to 8 mg/day  G2: Placebo | NR | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Resick et al., 2002[3](#_ENREF_3)  Resick et al., 2003[125](#_ENREF_125)Resick et al., 2012[126](#_ENREF_126) | G1: CBT, cognitive processing therapy  G2: CBT, exposure-based therapy (PE)  G3: WL | BDI  Mean (SD)  G1 Pre-tx: 23.70 (10.39)  G1 Post-tx: 12.73 (11.17)  G1 3 mth FU: 13.22 (11.64)  G1 9 mth FU: 14.17 (11.85)  G1 LTFU: 9.41 (11.13)  G2 Pre-tx: 24.03 (8.88)  G2 Post-tx: 16.00 (11.06)  G2 3 mth FU: 16.49 (11.62)  G2 9 mth FU: 16.41 (11.37)  G1 LTFU: 12.06 (12.68)  G3 Pre-tx: 23.33 (8.07)  G3 Post-tx: 22.62 (8.59)  G3 3 mth FU: 22.62 (8.59)  G3 9 mth FU: 22.62 (8.59)  Posttreatment differences, p<0.0001 3 mth FU differences, p<0.0001  9 mth FU differences, p<0.0001  LTFU differences, NS | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Resick et al., 2015[127](#_ENREF_127), [128](#_ENREF_128) | G1: CPT-C (Includes only the cognitive component of CPT)  G2: PCT | BDI-II  Mean (SE)  G1 Pre-tx: 27.9 (10.2)  G1 Post-tx: 19.9 (1.4)  G1 6-month followup: 21.1 (1.8)  G1 12-month followup: 22.7 (2.1)  G2 Pre-tx: 27.9 (12.2)  G2 Post-tx: 23.7 (1.4)  G2 6-month followup: 24.7 (1.7)  G2 12-month followup: 25.8 (2.1)  Piecewise linear model for BDI-II during followup G1: .57 (.44) (.11), p =.197 G2: .22 (.42), p = .608 Difference: .35 (.60), p = .555  Between group effect sizes (d): Baseline to posttreatment: -.3 Baseline to 6 months: -.3 Baseline to 1 year: -.3 | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Rothbaum et al., 1997[45](#_ENREF_45) | G1: EMDR  G2: WL | BDI Mean (SD) G1 Pre-tx: 21.4 (9.6) G1 Post-tx: 7.3 (5.5) G1 3 mth FU: 7.9 (5.3)  G2 Pre-tx: 34.8 (13.8) G2 Post-tx: 30.4 (15.7)  G1 vs. G2, p<0.05  STAI--State Mean (SD) G1 Pre-tx: 50.4 (10.6) G1 Post-tx: 31.8 (14.7) G1 3 mth FU: 37.3 (14.3)  G2 Pre-tx: 63.1 (21.0) G2 Post-tx: 48.5 (15.5)  STAI-Trait Mean (SD) G1 Pre-tx: 53.5 (10.9) G1 Post-tx: 35.0 (14.3) G1 3 mth FU: 37.3 (14.3)  G2 Pre-tx: 64.9 (11.1) G2 Post-tx 58.8 (11.1)  Post treatment G1 vs. G2, NS | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Rothbaum et al., 2005[13](#_ENREF_13) | G1: CBT, exposure-based therapy (PE)  G2: EMDR  G3: WL | BDI Mean (SD) G1 Pre-tx: 16.70 (8.18) G1 Post-tx: 4.65 (4.99) G1 6 mth FU: 4.44 (5.07)  G2 Pre-tx: 25.95 (7.11) G2 Post-tx: 10.70 (11.45) G2 6 mth FU: 10.53 (10.92)  G3 Pre-tx: 24.05 (10.50) G3 Post-tx: 22.20 (10.55)  Posttreatment G1 & G2 vs. G3, p<0.001  Posttreatment G1 vs G2, p=NS 6 mth FU G1 vs G2, p=NS  STAI-State  Mean (SD) G1 Pre-tx: 43.33 (12.59) G1 Post-tx: 30.00 (10.44) G1 6 mth FU: 29.19 (8.79)  G2 Pre-tx: 51.10 (11.05) G2 Post-tx: 32.60 (11.62) G2 6 mth FU: 38.89 (14.54) | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Rothbaum et al., 2005[13](#_ENREF_13)  (continued) |  | G3 Pre-tx: 46.58 (13.48)  G3 Post-tx: 49.00 (13.73)  Posttreatment G1 & G2 vs. G3, p<0.001  Posttreatment G1 vs G2, p=NS  6 mth FU G1 vs G2, p=NS  STAI-Trait  G1 Pre-tx: 48.72 (8.62)  G1 Post-tx: 35.56 (9.88)  G1 6 mth FU: 34.19 (7.52)  G2 Pre-tx: 56.80 (10.95)  G2 Post-tx: 41.10 (14.48)  G2 6 mth FU: 41.44 (13.26)  G3 Pre-tx: 53.42 (13.07)  G3 Post-tx: 53.95 (13.01)  Posttreatment G1 & G2 vs. G3, p<0.001  Posttreatment G1 vs G2, p=NR  6 mth FU G1 vs. G2, NR |  |  |  |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Ruglass et al., 2017 [143](#_ENREF_143) | G1: COPE  G2: Relaspe Prevention  G3: AMCG | SUI  Mean (SD)  G1 Pre-tx: 3.92 (2.69)  G1 Post-tx: 1.60 (2.46)  Change: -2.31 (95% CI, -3.23 to -1.39), p <0.001  G2 Pre-tx: 4.05 (2.35)  G2 Post-tx: 0.40 (0.52)  Change: -3.28 (95% -4.03 to -2.53), p <0.001  G3 Pre-tx: 3.79 (2.27)  G3 Post-tx: 2.85 (2.48)  Change: NR, ns  Treatment X Time Interaction, p <0.001  Between group differences  G1 vs G3: -0.97 (95%CI -1.72 to -0.22), p = 0.01  G2 vs G3: -2.07 (95%CI -2.92 to -1.21), p <0.001  G1 vs G2: -1.10 (95%CI -2.18 to -0.02, p =0.047 | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Sannibale et al. 2013[146](#_ENREF_146) | G1: IT (Integrated CBT for PTSD and AUD)  G2: AS, (CBT for AUD plus supportive counseling) | BDI-II  G1 Pre-tx: 30.37 (13.99)  G1 Post-tx: 25.13 (17.96)  G1 Followup 5 months: 26.79 (18.35)  G1 Followup 9 months: 23.38 (15.14)  G2 Pre-tx: 28.50 (9.15)  G2 Post-tx: 25.45 (12.52)  G2 Followup 5 months: 25.33 (12.53)  G2 Followup 9 months: 22.24 (14.82)  Treatment group\*time interaction ns  STAI-S  G1 Pre-tx: 55.89 (14.78)  G1 Post-tx: 48.83 (15.90)  G1 Followup 5 months: 53.17 (14.41)  G1 Followup 9 months: 52.00 (14.74)  G2 Pre-tx: 55.96 (10.80)  G2 Post-tx: 53.64 (10.47)  G2 Followup 5 months: 54.71 (14.30)  G2 Followup 9 months: 49.81 (14.76)  Treatment group\*time interaction ns | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Sannibale et al. 2013[146](#_ENREF_146)  (continued) |  | AUD diagnosis  n (%)  G1 Pre-tx: 33 (100)  G1 Post-tx: 16 (64)  G1 Followup 5 months: 10 (44)  G1 Followup 9 months: 14 (52)  G2 Pre-tx: 29 (100)  G2 Post-tx: 12 (50)  G2 Followup 5 months: 7 (33)  G2 Followup 9 months: 9 (43)  Treatment X time interaction ns |  |  |  |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Sautter et al., 2015[131](#_ENREF_131) | G1: SAT  G2: PFE | CES-D  Mean (SE)  G1 Pre-tx: 31.10 (2.18)  G1 Post-tx: 24.70 (2.43)  G1 12-week followup:  22.13 (2.43)  G2 Pre-tx: 30.21 (2.21)  G2 Post-tx: 28.48 (2.45)  G1 12 week followup:  28.22 (2.48)  Treatment X Time  Interaction at post-tx, t (79) = 1.45, p = 0.15  Treatment X Time  Interaction at 12 week followup, t (79) = 2.15, p = 0.04  STAI State  Mean (SE)  G1 Pre-tx: 49.66 (2.37)  G1 Post-tx: 39.61 (2.66)  G1 12 week followup: 37.69 (2.66)  G2 Pre-tx: 47.11 (2.41)  G2 Post-tx: 44.58 (2.67)  G1 12 week followup: 44.94 (2.71)  Treatment X Time Interaction at post-tx, t (79) = 2.10, p = 0.039  Treatment X Time Interaction at 12 week followup, t (79) = 2.72, p = 0.008 | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Schnurr et al., 2003[139](#_ENREF_139) | G1: Exposure-based, trauma-focused group therapy (psychoeducation, cognitive restructuring, relapse prevention, and coping skills training)  G2: Present-centered group Therapy(avoided trauma-focused references, cognitive restructuring, and other trauma-focused group therapy components) | NR | Only reported that there was no change on the Quality of Life Inventory.   SF-36 – Mental  Mean (SE)  G1: Pre-tx: 30.72 (0.86) G1 7 mth FU: 31.84 (0.73) G1 12 mth FU: 30.92 (0.81) Change at 7 mths, p>0.05 Change at 12 mths, p>0.05  G2 Pre-tx: 30.54 (0.85) G2 7 mth FU: 30.75 (0.73) G2 12 mth FU: 31.83 (0.79) Change at 7 mths, p>0.05  Change at 12 mths, p>0.05  SF-36- Physical  G1 Pre-tx: 41.78 (0.94) G1 7 mth FU: 40.35 (0.68) G1 12 mth FU: 40.24 (0.73) | GHQ  Mean (SE) G1 Pre-tx: 32.69 (0.55) G1 7 mth FU: 31.16 (0.49) G1 12 mth FU: 31.88 (0.53) Change at 7 mths, p<0.001  Change at 12 mths, p<0.05  G2 Pre-tx: 33.45 (0.54) G2 7 mth FU: 31.62 (0.49) G2 12 mth FU: 31.19 (0.53) Change at 7 mths, p<0.01  Change at 12 mths, p<0.001  Treatment Effect, NS  Treatment X Cohort, NS | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Schnurr et al., 2003[139](#_ENREF_139)  (continued) |  |  | Change at 7 mths, p>0.05 Change at 12 mths, p>0.05  G2 Pre-tx: 40.06 (0.95) G2 7 mth FU: 39.96 (0.68) G2 12 mth FU: 38.93 (0.71) Change at 7 mths, p>0.05  Change at 12 mths, p<0.01  Treatment Effect, NS  Treatment X Cohort, NS |  |  |
| Schnurr et al., 2007[138](#_ENREF_138) | G1: CBT, exposure-based therapy (PE)  G2: PCT | BDI  Baseline  Mean (95% CI)  G1: 25.3 (23.8 to 26.9)  G2: 23.9 (22.4 to 25.5)  Least Means (95% CI)  Immediate posttreatment  G1: 17.4 (15.3 to 19.5)  G2: 19.9 (18.0 to 21.9)  p=0.04  3-month followup  G1: 18.5 (16.3 to 20.7)  G2: 21.1 (19.1 to 23.1)  p=0.04 | QOL Inventory  Baseline  Mean (95 % CI)  G1: 0.06 (-0.24 to 0.35)  G2: 0.09 (-0.26 to 0.44)  Least Means (95% CI) Immediate posttreatment  G1: 0.56 (0.19 to 0.93)  G2: 0.24 (-0.12 to 0.60)  NS | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Schnurr et al., 2007[138](#_ENREF_138)  (continued) |  | 6-month followup  G1: 19.2 (17.1 to 21.3)  G2: 20.4 (18.2 to 22.7)  NS  Treatment effect, NS  Treatment X Time, NS  STAI  Baseline  Mean (95% CI)  G1: 52.1 (49.9 to 54.4)  G2: 52.4 (50.2 to 54.7)  Least Means (95% CI)  Immediate posttreatment  G1: 45.7 (42.6 to 48.7)  G2: 50.3 (47.4 to 53.3)  p=0.01  3-month followup  G1: 48.8 (45.9 to 51.8)  G2: 50.5 (47.7 to 53.3)  NS  6-month followup  G1: 50.4 (47.3 to 53.6)  G2: 50.8 (48.0 to 53.6)  NS  Treatment effect, NS  Treatment X Time, p<0.05 | 3-month followup  G1: 0.35 (-0.05 to 0.75)  G2: 0.22 (-0.14 to 0.60)  NS   6-month followup  G1: 0.23 (-0.12 to 0.58)  G2: 0.14 (-0.26 to 0.53)  NS  Treatment effect, NS  Treatment X Time, NS   SF-36-Mental  Baseline  Mean (95% CI) G1: 30.1 (28.4 to 31.7) G2: 30.6 (28.7 to 32.6)  Least Means (95% CI) Immediate posttreatment  G1: 37.5 (35.0 to 40.0)  G2: 33.4 (30.9 to 35.8)  p<0.01 |  |  |

| Author, Year | Intervention Groups | Comorbid l Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Schnurr et al., 2007[138](#_ENREF_138)  (continued) |  |  | 3-month followup G1: 35.6 (33.2 to 38.1) G2: 33.8 (31.1 to 36.4)  NS  6-month followup G1: 35.3 (33.0 to 37.7)  G2: 33.4 (30.9 to 35.9)  NS   Treatment effect, NS  Treatment X Time, NS  SF-36-Physical  Baseline  Mean (95% CI)  G1: 38.3 (36.4 to 40.2) G2: 39.7 (37.5 to 41.8)   Least Means (95% CI)  Immediate posttreatment  G1: 38.1 (36.1 to 40.2) G2: 39.5 (37.5 to 41.4)  NS |  |  |

| Author, Year | Intervention Groups | Comorbid Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Schnurr et al., 2007[138](#_ENREF_138)  (continued) |  |  | 3-month followup G1: 39.1 (37.1 to 41.1) G2: 38.8 (36.7 to 40.9)  NS   6-month followup G1: 38.8 (36.7 to 40.8)  G2: 38.3 (36.2 to 40.5)  NS  Treatment effect, NS  Treatment X Time, NS |  |  |

| Author, Year | Intervention Groups | Comorbid Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Schnyder et al., 2011[49](#_ENREF_49) | G1: Eclectic psychotherapy  BEP  G2: WL (Minimal attention) | HADS - Anxiety  Mean (SD)  G1 Pre-tx:14.4 (2.6)  G1 Post-tx:12.2 (4.2)  G1 6 mth FU: 11.8 (5.4)  G2 Pre-tx:13.8 (2.5)  G2 Post-tx:13.5 (3.1)  Group Effect, p<0.05  HADS - Depression  G1 Pre-tx:13.4 (4.8)  G1 Post-tx:10.8 (5.8)  G1 6 mth FU: 11.4 (5.6)  G2 Pre-tx: 10.7 (3.5)  G2 Post-tx: 11.4 (4.2)  Group Effect, p<0.05 | NR | NR | NR |
| Simon et al., 2008[174](#_ENREF_174) | G1: Paroxetine  12.5 to 62.5 mg/day  G2: Placebo  and 5 additional sessions of PE | NR | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Sloan et al., 2012[17](#_ENREF_17) | G1: Sertraline 25 to 200mg/day  G2: Venlafaxiene 37.5 to 375mg/day  Sertraline 25 to 200mg/day | NR | NR | NR | NR |
| Sonne et al., 2016[186](#_ENREF_186) | G1: WET  G2: WL | HAM-D (ITT)  Mean (SE)  G1 Pre-tx: 23.69 (0.55)  G1 Post-tx: 22.33 (0.85)  Difference: 1.36 (0.79), p =0.08, Effect size: 0.24  G2 Pre-tx: 23.69 (0.62)  G2 Post-tx: 22.46 (0.89)  Difference: 1.23 (0.82), p =0.13, Effect size: 0.22  Group difference for difference between pre- and post-treatment ratings:0.13 (1.14), p = 0.91, Effect size: 0.02  Group differences at follow up: Regression coefficient, B = 0.19 (95% CI, -1.94 to 2.33), Beta-coefficient = 0.01, SE = 1.09, p = 0.86 | WHO-5 (ITT)  Mean (SE)  G1 Pre-tx: 12.73 (1.36)  G1 Post-tx: 22.21 (2.67)  Difference: -9.48 (2.42), p <0.01, Effect size: 0.65  G2 Pre-tx: 15.00 (1.64)  G2 Post-tx: 17.75 (2.24)  Difference: -2.75 (2.16), p =0.20, Effect size: 0.19  Group difference for difference between pre- and post-treatment ratings:6.73 (3.24), p = 0.04, Effect size: 0.47 | SDS (ITT)  Mean (SE)  G1 Pre-tx: 24.65 (0.53)  G1 Post-tx: 21.81 (0.88)  Difference: 2.84 (0.85), p <0.01, Effect size: 0.48  G2 Pre-tx: 22.71 (0.69)  G2 Post-tx: 23.20 (0.79)  Difference: -0.49 (0.86), p =0.57, Effect size: 0.08  Group difference for difference between pre- and post-treatment ratings:3.32 (1.21), p < 0.01, Effect size: 0.56  Group differences at follow up: Regression coefficient, B = 2.31 (95% CI, 0.10 to 4.52), Beta-coefficient = 0.16, SE = 1.13, p = 0.04  SAS-SR(ITT)  Mean (SE)  G1 Pre-tx: 2.93 (0.07)  G1 Post-tx: 2.68 (0.08)  Difference: 0.25 (0.07), p <0.01, Effect size: 0.36 | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Sonne et al., 2016[186](#_ENREF_186)  (continued) |  | HAM-A (ITT)  Mean (SE)  G1 Pre-tx: 26.74 (0.68)  G1 Post-tx: 26.41 (1.04)  Difference: 0.33 (0.97), p = 0.73, Effect size: 0.05  G2 Pre-tx: 27.14 (0.72)  G2 Post-tx: 26.05 (1.05)  Difference: 1.09 (1.00), p =0.28, Effect size: 0.16  Group difference for difference between pre- and post-treatment ratings:-0.76 (1.39), p = 0.58, Effect size: 0.11  Group differences at follow up: Regression coefficient, B = -0.57 (95% CI, -3.19 to 2.04), Beta-coefficient = -0.03, SE = 1.34, p = 0.67 | Group differences at follow up: Regression coefficient, B = -5.79 (95% CI, -12.05 to 0.46), Beta-coefficient = -0.13, SE = 3.19, p = 0.07 | G2 Pre-tx: 2.96 (0.07)  G2 Post-tx: 2.80 (0.08)  Difference: 0.16 (0.08), p =0.04, Effect size: 0.23  Group difference for difference between pre- and post-treatment ratings: 0.09 (0.11), p = 0.39, Effect size: 0.13  Group differences at follow up: Regression coefficient, B = 0.10 (95% CI, -0.09 to 0.29), Beta-coefficient = 0.07, SE = 0.10, p = 0.29  GAF-S(ITT)  Mean (SE)  G1 Pre-tx: 47.43 (0.57)  G1 Post-tx: 51.33 (0.93)  Difference: -3.90 (0.79), p <0.01, Effect size: 0.68  G2 Pre-tx: 48.14 (0.61)  G2 Post-tx: 51.82 (0.94)  Difference: -3.68 (1.03), p <0.01, Effect size: 0.64  Group difference for difference between pre- and post-treatment ratings: 0.22 (1.29), p = 0.86, Effect size: 0.04 |  |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Sonne et al., 2016[186](#_ENREF_186)  (continued) |  | HSCL-25 (ITT)  Mean (SE)  G1 Pre-tx: 3.03 (0.05)  G1 Post-tx: 2.85 (0.07)  Difference: 0.18 (0.07), p <0.01, Effect size: 0.39  G2 Pre-tx: 3.04 (0.05)  G2 Post-tx: 2.94 (0.06)  Difference: 0.10 (0.05), p =0.05, Effect size: 0.22  Group difference for difference between pre- and post-treatment ratings:0.08 (0.09), p = 0.37, Effect size: 0.17  Group differences at follow up: Regression coefficient, B = 0.07 (95% CI, -0.10 to 0.23), Beta-coefficient = 0.05, SE = 0.08, p = 0.42 |  | GAF Group differences at follow up: Regression coefficient, B = 0.06 (95% CI, -2.37 to 2.48), Beta-coefficient = 0.00, SE = 1.24, p = 0.96  -F(ITT)  Mean (SE)  G1 Pre-tx: 48.37 (0.68)  G1 Post-tx: 50.28 (0.92)  Difference: -1.91 (0.79), p = 0.02, Effect size: 0.29  G2 Pre-tx: 49.04 (0.68)  G2 Post-tx: 51.91 (0.96)  Difference: -2.87 (0.89), p <0.01, Effect size: 0.43  Group difference for difference between pre- and post-treatment ratings: 0.96 (1.19), p = 0.42, Effect size: 0.06  Group differences at follow up: Regression coefficient, B = 1.22 (95% CI, -1.03 to 3.47), Beta-coefficient = 0.08, SE = 1.15, p = 0.29 |  |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Sonne et al., 2016[186](#_ENREF_186)  (continued) |  | SCL-90 (ITT)  Mean (SE)  G1 Pre-tx: 2.40 (0.058)  G1 Post-tx: 2.35 (0.10)  Difference: 0.05 (0.10), p = 0.64, Effect size: 0.06  G2 Pre-tx: 2.50 (0.08)  G2 Post-tx: 2.53 (0.09)  Difference: -0.03 (0.07), p =0.69, Effect size: 0.04  Group difference for difference between pre- and post-treatment ratings:0.08 (0.12), p = 0.54, Effect size: 0.10  Group differences at follow up: Regression coefficient, B = 0.12 (95% CI, -0.12 to 0.35), Beta-coefficient = 0.07, SE = 0.12, p = 0.31 |  |  |  |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Spence et al., 2011[30](#_ENREF_30) | G1: CBT-mixed  (Imaginal exposure, Coping skills, Cognitive processing)  G2: WL | Patient Health Questionaire-9 item  G1 Pre-tx: 15.61 (4.38)  G1 Post-tx: 10.17 (5.65)  G1 3 mth FU: 9.91 (6.12)  G2 Pre-tx: 15.05 (4.90)  G2 Post-tx: 13.84 (4.95)  G2 3 mth FU: NR  G1 vs. G2, p<0.01  Generalized Anxiety Disorder Scale  G1 Pre-tx: 12.91 (4.57)  G1 Post-tx: 7.91 (5.98)  G1 3 mth FU: 7.26 (5.94)  G2 Pre-tx: 11.11 (3.89)  G2 Post-tx: 10.63 (3.53)  G2 3 mth FU: NR  G1 vs. G2 @ 8 weeks:  p<0.04\*\* | NR | SDS G1 Pre-tx: 18.17 (6.96)  G1 Post-tx: 13.22 (9.42)  G1 3 mth FU: 11.30 (9.64)  G2 Pre-tx: 19.42 (8.03) G2 Post-tx: 18.11 (6.67) G2 3 mth FU: NR  G1 vs G2, p=0.07 | NR |

| Author, Year | Intervention Groups | Comorbid Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Stein et al., 2002[80](#_ENREF_80) | G1: Olanzapine  10 to 20 mg  G2: Placebo | CES -D  G1: -5.25 (SD=6.27)  G2: 4.88 (SD=9.66)  p<.03 | NR | NR | NR |
| Tarrier et al., 1999[129](#_ENREF_129)  Tarrier et al., 1999[130](#_ENREF_130) | G1: CBT, exposure-based therapy  G2: CBT, cognitive restructuring,  Cognitive Therapy | BDI  Mean (SD) G1 Pre-tx: 23.93 (10.95)  G1 Post-tx: 17.43 (11.88) G1 6-mth FU: 20.41 (10.60)  G2 Pre-tx: 27.45 (12.39)  G2 Post-tx: 19.03 (13.20) G2 6 mth FU: 20.83 (12.79)  G1 vs. G2 differences, NS  12-Month Followup G1 Pre-tx: 23.52 (10.87) G1 12 mth FU: 20.33 (11.40)  G2 Pre-tx: 26.90 (12.34) G2 12 mth FU: 20.93 (13.55)  G1 vs. G2 differences, NS | NR | NR | Percentage Back at Work 6 Month Followup Overall: 40% G1: 44% G2: 37% |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Tarrier et al., 1999[129](#_ENREF_129)  Tarrier et al., 1999[130](#_ENREF_130)  (continued) |  | BAI Mean (SD) G1 Pre-tx: 26.86 (10.75) G1 6 mth FU: 23.04 (12.18)  G2 Pre-tx: 26.39 (12.05) G2 6 mth FU: 20.66 (12.97)  G1 vs. G2 differences, NS  12-Month Followup G1 Pre-tx: 26.76 (10.23) G1 12 mth FU: 20.58 (13.01)  G2 Pre-tx: 26.34 (12.32) G2 12 mth FU: 21.54 (14.13)  G1 vs. G2 differences, NS |  |  |  |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Taylor et al., 2003[133](#_ENREF_133) | G1: CBT, exposure-based therapy  G2: EMDR  G3: Relaxation Training | BDI  Mean (SD)  G1 Pre-tx: 26.4 (10.0)  G1 Post-tx: 16.04 (9.1)  G1 FU: 14.4 (11.0)  G2 Pre-tx: 23.2 (7.8)  G2 Post-tx: 13.0 (10.6)  G2 FU: 12.7 (8.9)  G3 Pre-tx: 26.3  (11.1)  G3 Post-tx: 21.0 (13.8)  G3 FU: 16.7 (8.9)  Treatment Effects, NS  Treatment X Time, NS  Time Effect from Post-tx to FU, p 0.01 | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| ter Heide et al., 2016[43](#_ENREF_43) | G1: EMDR  G2: Stabilisation | HSCL, anxiety  G1 vs. G2, d = 0.09, NS  HSCL, depression  G1 vs. G2, d = -0.03, NS | WHOQOL-BREF, physical  G1 vs. G2, d = 0.07, NS  WHOQOL-BREF, psychological  G1 vs. G2, d = 0.07, NS  WHOQOL-BREF, social relationships  G1 vs. G2, d = -0.28, NS  WHOQOL-BREF, environment  G1 vs. G2, d = -0.52, NS | NR | NR |
| Tucker et al., 2001[65](#_ENREF_65) | G1: Paroxetine  20 to 50mg/day  G2: Placebo | MADRS Adjusted Mean Differences (95% CI), G1 vs. G2 -3.9 (-6.4 to -1.2) | NR | SDS Adjusted Mean Differences (95% CI), G1 vs. G2 -2.6 (-4.4 to -0.7) | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Tucker et al., 2003[175](#_ENREF_175)  Tucker et al., 2004[176](#_ENREF_176) | G1: Citalopram  20 to 50 mg/day  G2: Sertraline  50 to 200 mg/day  G3: Placebo | RefId 824 Systolic BP difference G1 Pre-tx: 6.66  G1 Post-tx: 0.70  G2 Pre-tx: 4.20  G2 Post-tx: -0.11  G3 Pre-tx: 7.25 G3 Post-tx: 1.00  Between group differences, NS  Diastolic BP G1 Pre-tx: 2.28  G1 Post-tx: -1.65  G2 Pre-tx: 2.22  G2 Post-tx: 0.47  G3 Pre-tx: 5.60  G3 Post-tx: -2.93  Between group differences, NS | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Tucker et al., 2003[175](#_ENREF_175)  Tucker et al., 2004[176](#_ENREF_176)  (continued) |  | Heart rate difference  Mean (SD)  G1 Pre-tx: 3.22 (5.16)  G1 Post-tx:1.65 (3.00)  G2 Pre-tx: 2.20 (3.56)  G2 Post-tx: 1.69 (3.75)  G3 Pre-tx: 0.85 (1.00)  G3 Post-tx: 0.57 (2.75)  Between group differences, NS  BDI  G1 Pre-tx: 29.72(13.93)  G1 Post-tx: 13.65 (11.06)  G2 Pre-tx: 27.09 (12.25)  G2 Post-tx: 13.67 (14.56)  G3 Pre-tx: 31.60 (9.38)  G3 Post-tx: 16.00 (17.21)  Between group differences, p value NR |  |  |  |
| Tucker et al., 2007[78](#_ENREF_78) | G1: Topiramate  25 to 400mg/day; given 2 times a day  G2: Placebo | HAM-A  Mean Percentage Change (SD)  G1: -53.9 (42.8)  G2: -40.0 (44.2)  p= 0.331  HAM-D  Mean Percentage Change (SD)  G1 -50.7 (45.6)  G2 -33.3 (46.8)  p= 0.253 | Sexual Functioning Scale  Mean Percentage Change (SD) G1: 2.58 (31.2) G2: 16.2 (20.4) p= 0.120 | SDS  Mean Percentage Change (SD) G1: -30.6 (56.4) G2: -35.4 (61.9)  p=0.804 | NR |

| Author, Year | Intervention Groups | | Comorbid Medical Condition | | QOL | Disability/Functional Impairment | | Return to Work/Active Duty OR Ability to Work | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Van Dam et al., 2013[262](#_ENREF_262) | | G1: SWT plus TAU  G2: TAU (regular intensive  treatment program for SUD based on CBT) | TLFB (days abstinent)  Mean (SD)  G1 Pre-tx: 19.9 (29.3)  G1 Post-tx: 76.8 (15.5)  G1 Followup 3 months: 61.0 (30.8)  G2 Pre-tx: 20.1 (25.4)  G2 Post-tx:66.0 (30.3)  G2 Followup 3 months: 58.6 (38.4)  Treatment X time Interaction, F(2,34) = 0.48, p = 0.620, η2 = 0.15  SUD in Remission (Primary SUD diagnosis)  N (%)  G1 Pre-tx: 1 (5.3)  G1 Post-tx: 16.6 (87.4)  G2 Pre-tx: 3 (20.0)  G2 Post-tx: 10.2 (68.0)  G1 vs. G2 post-tx differences NS, p’s>0.23 | NR | | | NR | | NR |
| van den Berg et al., 2015[16](#_ENREF_16) | | G1: PE  G2: EMDR  G3: WL | NR | NR | | | NR | | NR |
| van der Kolk et al., 1994[63](#_ENREF_63) | | G1: Fluoxetine  20 to 60mg/day  G2: Placebo | HAM-D Difference in Improvement G1 vs. G2 = 7.11  ANCOVA Results F = -7.11, t = -3.72, p=0.0006 | NR | | | NR | | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| van der Kolk et al., 2007[47](#_ENREF_47) | G1: EMDR  G2: Fluoxetine  10 to 60 mg/day  G3: Placebo | BDI-II  Mean (SD)  G1 Pre-tx:  G1 Post-tx: 9.10 (6.02)  G1 6 mth FU: 5.25 (5.23)  G2 Pre-tx:  G2 Post-tx: 13.00 (8.66)  G2 6 mth FU: 14.00 (7.71)  G3 Pre-tx:  G3 Post-tx: 14.38 (9.74)  G3: NA  Treatment effect, NS  Posttreatment  G1 vs. G2, p= 0.08  G1 vs. G3, p=0.07  G2 vs. G3, p=0.94  Followup  G1 vs. G2, p<.001 | NR | NR | NR |
| van der Kolk et al., 2016[162](#_ENREF_162) | G1: Neurofeedback  G2: WL | NR | NR | IASC is available. Only subscales reported. | NR |

| Author, Year | Intervention Groups | Comorbid Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| van Emmerik et al., 2008[40](#_ENREF_40) | G1: CBT-Mixed  Psychoeducation, prolonged exposure, imaginal exposure, exposure in vivo, cognitive exposure  G2: SWT  G3: WL | BDI Mean (SD) G1 Pre-tx: 20.52 (9.43)  G1 Post-tx: 15.31 (9.44)  G1 FU: 14.79 (9.48)  G2 Pre-tx: 22.55 (10.63)  G2 Post-tx: 19.39 (13.38)  G2 FU: 18.65 (13.56)  G3 Pre-tx: 21.24 (8.88) G3 Post-tx: 20.66 (10.77) G3 FU: 21.17 (11.13)  Group X Time Effect  G1 vs G2, p=0.51 G1+G2 vs G3, p<0.04  STAI-State  Mean (SD) G1 Pre-tx: 55.44 (11.22)  G1 Post-tx: 46.51 (14.32)  G1 FU: 46.90 (15.02)  G2 Pre-tx: 54.22 (11.90)  G2 Post-tx: 47.49 (15.75)  G2 FU: 46.70 (15.09)  G3 Pre-tx: 57.14 (11.60) G3 Post-tx: 54.06 (12.18)  G3 FU: 55.08 (12.83)  Group X Time Effect  G1 vs. G2, p=0.81 G1+G2 vs G3, p=0.05 | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| van Emmerik et al., 2008[40](#_ENREF_40)  (continued) |  | STAI-Trait G1 Pre-tx: 50.54 (8.49)  G1 Post-tx: 46.23 (9.80)  G1 FU: 48.15 (9.00)  G2 Pre-tx: 50.35 (7.33)  G2 Post-tx: 47.62 (8.81)  G2 FU: 47.19 (8.76)  G3 Pre-tx: 53.20 (8.70)  G3 Post-tx: 52.23 (7.31) G3: 52.06 (7.28)  Group X Time G1 vs G2, p=0.37 G1+G2 vs G3, p=0.20 |  |  |  |
| Wells et al., 2014[19](#_ENREF_19) | G1: Metacognitive therapy  G2: PE  G3: WL | BDI-II  Mean (SD) G1 Pre-tx: 29.9 (5.48)  G1 Post-tx: 9.1 (6.79)  G1 3 month followup: 12.6 (13.53)  Mean difference, post-tx: 20.8 (SE, 3.48), p <0.0005, (95% CI, 12.93 to 28.67)  G2 Pre-tx: 32.5 (10.06)  G2 Post-tx: 17.9 (13.09)  G2 3 month followup: 17.1 (14.59)  Mean difference, post-tx: 14.6 (4.18), p = 0.007, (95% CI, 5.16 to 24.04)  G3 Pre-tx: 40.7 (10.66) G3 Post-tx: 40 (8.68) G3 3 month followup: NA | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Wells et al., 2014[19](#_ENREF_19) (continued) |  | Mean difference, post-tx: 0.7 (1.56), p > 0.05, (95% CI, -2.84 to 4.24)  Treatment X time interaction, post-tx: F=9.94, p = 0.001  Hedge's g: G1 Pre-Post: 1.73 G2 Pre-Post: 1.01 G1 Pre-FU: 1.01 G2 Pre-FU: 0.9  ANCOVA group effect: F = 16.53, p < 0.0005 G1 vs G3 Pre-Post: 26.09 (SE, 4.63), p < 0.0005, (95% CI, 14.26 to 37.93) G2 vs G3 Pre-Post: 18.45 (4.42), p = 0.001, (95% CI, 7.15 to 29.75) G1 vs G2 Pre-Post: 7.64 (4.15), p > 0.05, (95% CI, -2.96 to 18.25)  ANCOVA group effects at followup  G1 vs. G2: F = 0.39, p = 0.54  BAI  Mean (SD) G1 Pre-tx: 29.5 (7.69)  G1 Post-tx: 8.6 (6.06)  G1 3 month followup: 12 (13.57)  Mean difference, post-tx: 20.9 (SE = 2.77), p <0.0005, (95% CI, 14.64 to 27.16) |  |  |  |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Wells et al., 2014[19](#_ENREF_19) (continued) |  | G2 Pre-tx: 31.5 (10.32)  G2 Post-tx: 15.3 (11.89)  G2 3 month followup: 13.1 (7.4)  Mean difference: 16.2 (Se = 3.93), p = 0.003, (95% CI, 7.31 to 25.09)  G3 Pre-tx: 36.8 (16.22)  G3 Post-tx: 34.3 (15.00) G3 3 month followup: NA  Mean differences, post-tx: 2.5 (SE = 1.86), (95% CI, -1.70 to 6.70)  Treatment X time: F=10.33, p < 0.0005  Hedge's g: G1 Pre-Post: 2.18 G2 Pre-Post: 1.19 G1 Pre-FU: 1.09 G2 Pre-FU: 1.34  ANCOVA group effect: F = 14.63, p < 0.0005 G1 vs G3 Pre-Post: 20.88 (SE = 4), p < 0.0005, (95% CI, 10.64 to 31.11) G2 vs G3 Pre-Post: 15.5 (SE = 3.94), p = 0.002, (95% CI, 5.42 to 25.57) G1 vs G2 Pre-Post: 5.38 (3.88), p = ns, (95% CI, -15.30 to 4.54)  ANCOVA group effects at followup  G1 vs. G2: F = 0.04, p = 0.85 |  |  |  |

| Author, Year | | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work | |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Yeh et al., 2011[79](#_ENREF_79) | | G1: Topiramate  25 to 200mg/day  G2: Placebo | BDI Mean(SD) G1 Pre-tx: 22.29 (9.47) G1 Post-tx 13.81 (10.29)  G2 Pre-tx: 22.0 (11.80) G2 Post-tx:18.14 (14.77)  Between Group Change, p=0.72 | NR | NR | NR | |
| Zlotnick et al., 2009[56](#_ENREF_56) | | G1: Seeking Safety;  G2: Usual care  Psychoeducational group and individual case management and drug counseling | Addicition Severity Index Mean difference (95% CI)  0.01 (-0.06 to -0.08) | NR | NR | NR | |
| Zohar et al., 2002[72](#_ENREF_72) | G1: Sertraline  50 to 200 mg/day  G2: Placebo | | MADRS  Mean Change from Baseline (SD)  G1: -9.17 (3.13)  G2: -5.96 (3.33)  NS | NR | NR | | NR |

ANOVA = analysis of variance; ANCOVA = analysis of covariance; BAI = Beck Anxiety Inventory; BDI = Beck Depression Inventory; CES-D = Center for Epidemiologic Studies Depression Scale; CI = confidence interval; FU = Followup; GAF = Global Assessment of Functioning; GHQ-28 = General Health Questionnaire (28 item); HADS-A =Hospital Anxiety Scale; HADS-D = Hospital Depression Scale; HAM-A = Hamilton Rating Scale for Anxiety; HAM-D = Hamilton Rating Scale for Depression; MADRS = Montgomery–Åsberg Depression Rating Scale; NR= not reported; NS = not significant; PHQ = The Patient Health Questionnaire; Pre-tx = pretreatment; Post-tx = Posttreatment; PTSD= Post-Traumatic Stress Disorder; Q-LES-Q-SF = Quality of Life Enjoyment and Satisfaction Questionnaire – Short Form; QOL = quality of life; RMANOVA, repeated measures analysis of variance; SD = standard deviation; SDS = Sheehan Disability Scale; SE = standard error; SF-36 = Short Form (36) Health Survey; SF-36V =Veterans Short Form 36 Questionnaire; STAI = State-Trait Anxiety Inventory; SUI = Substance Use Inventory.